<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0110245996
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Atomibe
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ATORVASTATIN CALCIUM,EZETIMIBE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10,10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        116.25
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Ind Swift Limited&#x9;" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Ind Swift Limited	
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2950]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C10BA05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Product name, active substance(s) and Pharmacotherapeutic group:</strong></p><p><strong>&nbsp;</strong></p><p><strong>ATOMIBE 10mg/10mg (Ezetimibe 10mg/Atorvastatin 10 mg)</strong></p><p>Each film coated tablet contains Atorvastatin 10 mg</p><p>Ezetimibe&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 10mg</p><p>Excipients&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; q.s.</p><p>&nbsp;</p><p>ATOMIBE 10mg/20mg (Ezetimibe 10mg/Atorvastatin 20 mg)</p><p>Each film coated tablet contains Atorvastatin 20 mg</p><p>Ezetimibe&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 10mg</p><p>Excipients&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; q.s</p><p>&nbsp;</p><p>ATOMIBE 10mg/40mg (Ezetimibe 10mg/Atorvastatin 40 mg)</p><p>Each film coated tablet contains Atorvastatin&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 40 mg</p><p>Ezetimibe&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 10mg</p><p>Excipients&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; q.s</p><p>&nbsp;</p><p>For the full list of excipients, see section 6 (a).</p><p>&nbsp;</p><p>Pharmacotherapeutic group: Lipid modifying agents, HMG-CoA reductase inhibitors in combination with other lipid modifying agents, ATC code: C10BA05</p><p>&nbsp;</p><p>ATOMIBE is a lipid-lowering product that selectively inhibits the intestinal absorption of cholesterol and related plant sterols and inhibits the endogenous synthesis of cholesterol.</p><p>&nbsp;</p><p>Therapeutic indications:</p><p><strong>&nbsp;</strong></p><p><em>Prevention of Cardiovascular Events</em></p><p>ATOMIBE is indicated to reduce the risk of cardiovascular events in patients with coronary heart disease (CHD) and a history of acute coronary syndrome (ACS), either previously treated with a statin or not.</p><p>&nbsp;</p><p><em>Hypercholesterolaemia</em></p><p><u>ATOMIBE is indicated</u> as adjunctive therapy to diet for use in adults with primary (heterozygous familial and non-familial) hypercholesterolaemia or mixed hyperlipidaemia where use of a combination product is appropriate.</p><p>&bull;&nbsp; patients not appropriately controlled with a statin alone</p><p>&bull;&nbsp; patients already treated with a statin and ezetimibe</p><p><!--[if gte vml 1]><o:wrapblock><v:shape
  id="_x0000_s1026" style='position:absolute;margin-left:90pt;margin-top:12.6pt;
  width:112.6pt;height:.1pt;z-index:-251658240;mso-wrap-distance-left:0;
  mso-wrap-distance-right:0;mso-position-horizontal-relative:page'
  coordorigin="1800,252" coordsize="2252,0" path="m1800,252r2252,e" filled="f"
  strokeweight=".6pt">
  <v:path arrowok="t"/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="151" height="1" src="file:///C:/Users/Muhammed/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p><em>Homozygous Familial Hypercholesterolaemia (HoFH)</em></p><p>ATOMIBE is indicated as adjunctive therapy to diet for use in adults with HoFH. Patients may also receive adjunctive treatments (e.g. low-density lipoprotein [LDL] apheresis).</p><p>&nbsp;</p><p>Information on the benefits of using this medicine:</p><p><!--[if gte vml 1]><o:wrapblock><v:shape
  id="_x0000_s1027" style='position:absolute;margin-left:90pt;margin-top:10.45pt;
  width:263.7pt;height:.1pt;z-index:-251657216;mso-wrap-distance-left:0;
  mso-wrap-distance-right:0;mso-position-horizontal-relative:page'
  coordorigin="1800,209" coordsize="5274,0" path="m1800,209r5274,e" filled="f"
  strokeweight=".6pt">
  <v:path arrowok="t"/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="353" height="1" src="file:///C:/Users/Muhammed/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p>It is a medicine to lower increased levels of cholesterol and contains ezetimibe and atorvastatin.</p><p>&nbsp;</p><p>ATOMIBE is used in adults to lower levels of total cholesterol, &ldquo;bad&rdquo; cholesterol (LDL cholesterol), and fatty substances called triglycerides in the blood. In addition, ATOMIBE raises levels of &ldquo;good&rdquo; cholesterol (HDL cholesterol).</p><p>&nbsp;</p><p>ATOMIBE works to reduce your cholesterol in two ways. It reduces the cholesterol absorbed in your digestive tract, as well as the cholesterol your body makes by itself.</p><p>&nbsp;</p><p>Cholesterol is one of several fatty substances found in the bloodstream. Your total cholesterol is made up mainly of LDL and HDL cholesterol.</p><p>&nbsp;</p><p>LDL cholesterol is often called &ldquo;bad&rdquo; cholesterol because it can build up in the walls of your arteries forming plaque. Eventually this plaque build-up can lead to a narrowing of the arteries. This narrowing can slow or block blood flow to vital organs such as the heart and brain. This blocking of blood flow can result in a heart attack or stroke.</p><p>&nbsp;</p><p>HDL cholesterol is often called &ldquo;good&rdquo; cholesterol because it helps keep the bad cholesterol from building up in the arteries and protects against heart disease.</p><p>Triglycerides are another form of fat in your blood that may increase your risk for heart disease.</p><p>&nbsp;</p><p>ATOMIBE is used for patients who cannot control their cholesterol levels by diet alone. You should stay on a cholesterol-lowering diet while taking this medicine.</p><p>&nbsp;</p><p>ATOMIBE is used in addition to your cholesterol-lowering diet if you have:</p><p>&nbsp;</p><p>&bull;&nbsp; A raised cholesterol level in your blood (primary hypercholesterolaemia [heterozygous familial and non-familial]) or elevated fat levels in your blood (mixed hyperlipidaemia)</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp; That is not well controlled with a statin alone; for which you have used a statin and ezetimibe as separate tablets.</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp; A hereditary illness (homozygous familial hypercholesterolaemia) that increases the cholesterol level in your blood. You may also receive other treatments.</p><p>&nbsp;</p><p>&bull;&nbsp; Heart disease. ATOMIBE reduces the risk of heart attack, stroke, surgery to increase heart blood flow, or hospitalisation for chest pain.</p><p>&nbsp;</p><p>ATOMIBE does not help you lose weight.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>&nbsp;</strong></p><p><strong>a.&nbsp;&nbsp; </strong><strong>Do not take ATOMIBE:</strong></p><p>If you are allergic to pregabalin or any of the other ingredients of this medicine (listed in section 6).</p><p>&bull;&nbsp; you have or have ever had a disease that affects the liver,</p><p>&bull;&nbsp; you have had any unexplained abnormal blood tests for liver function,</p><p>&bull;&nbsp; you are a woman able to have children and are not using reliable contraception,</p><p>&bull;&nbsp; you are pregnant, trying to become pregnant or are breast-feeding,</p><p>&bull;&nbsp; you use the combination of glecaprevir/pibrentasvir in the treatment of hepatitis C.</p><p>&nbsp;</p><p>b.&nbsp;&nbsp; Take special care with the product</p><p>Talk to your doctor or pharmacist before taking ATOMIBE if.</p><p>&bull;&nbsp;&nbsp; you have had a previous stroke with bleeding into the brain, or have small pockets of fluid in the brain from previous strokes,</p><p>&bull;&nbsp; you have kidney problems,</p><p>&nbsp;</p><p>&bull;&nbsp; you have an under-active thyroid gland (hypothyroidism),</p><p>&bull;&nbsp;&nbsp; you have had repeated or unexplained muscle aches or pains, a personal history or family history of muscle problems,</p><p>&bull;&nbsp;&nbsp; you have had previous muscular problems during treatment with other lipid-lowering medicines (e.g. other &ldquo;statin&rdquo; or &ldquo;fibrate&rdquo; medicines),</p><p>&bull;&nbsp; you regularly drink a large amount of alcohol,</p><p>&bull;&nbsp; you have a history of liver disease,</p><p>&bull;&nbsp; you are older than 70 years,</p><p>&bull;&nbsp; you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this product,</p><p>&bull;&nbsp;&nbsp; you are taking or have taken in the last 7 days a medicine called fusidic acid, (a medicine for bacterial infection) orally or by injection. The combination of fusidic acid and ATOMIBE can lead to serious muscle problems (rhabdomyolysis).</p><p>&nbsp;</p><p><strong>Contact your doctor promptly if you experience unexplained muscle pain, tenderness, or weakness while taking ATOMIBE. </strong>This is because on rare occasions, muscle problems can be serious, including muscle breakdown resulting in kidney damage. Atorvastatin is known to cause muscle problems, and cases of muscle problems have also been reported with ezetimibe.</p><p>&nbsp;</p><p>Also tell your doctor or pharmacist if you have a muscle weakness that is constant. Additional tests and medicines may be needed to diagnose and treat this.</p><p>Check with your doctor or pharmacist before taking ATOMIBE</p><p>&bull;&nbsp; if you have severe respiratory failure.</p><p>&nbsp;</p><p>If any of these apply to you (or you are not sure), talk to your doctor or pharmacist before taking ATOMIBE because your doctor will need to carry out a blood test before and possibly during your ATOMIBE treatment to predict your risk of muscle-related side effects. The risk of muscle-related side effects, e.g. rhabdomyolysis, is known to increase when certain medicines are taken at the same time (see section 2 &ldquo;Other medicines and ATOMIBE&rdquo;).</p><p>&nbsp;</p><p>While you are on this medicine your doctor will monitor you closely if you have diabetes or are at risk of developing diabetes. You are likely to be at risk of developing diabetes if you have high levels of sugars and fats in your blood, are overweight and have high blood pressure.</p><p>&nbsp;</p><p>Tell your doctor about all your medical conditions including allergies.</p><p>&nbsp;</p><p>The combined use of ATOMIBE and fibrates (medicines for lowering cholesterol) should be avoided since the combined use of ATOMIBE and fibrates has not been studied.</p><p>&nbsp;</p><p>Children</p><p>ATOMIBE is not recommended for children and adolescents.</p><p>&nbsp;</p><p>c.&nbsp;&nbsp; Taking or using other medicines, herbal or dietary supplements</p><p>Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other</p><p>There are some medicines that may change the effect of ATOMIBE or their effect may be changed by ATOMIBE (see section 3). This type of interaction could make one or both of the medicines less effective. Alternatively it could increase the risk or severity of side effects, including the important muscle wasting condition known as &ldquo;rhabdomyolysis&rdquo; described in section 4:</p><p>&bull;&nbsp; ciclosporin (a medicine often used in organ transplant patients),</p><p>&bull;&nbsp;&nbsp; erythromycin, clarithromycin, telithromycin, fusidic acid**, rifampicin (medicines for bacterial infections),</p><p>&bull;&nbsp;&nbsp;&nbsp; ketoconazole, itraconazole, voriconazole, fluconazole, posaconazole (medicines for fungal infections),</p><p>&bull;&nbsp;&nbsp;&nbsp; gemfibrozil, other fibrates, nicotinic acid, derivatives, colestipol, cholestyramine (medicines for regulating lipid levels),</p><p>&bull;&nbsp; some calcium channel blockers used for angina or high blood pressure, e.g. amlodipine, diltiazem,</p><p>&bull;&nbsp; digoxin, verapamil, amiodarone (medicines to regulate your heart rhythm),</p><p>&bull;&nbsp; medicines used in the treatment of HIV, e.g. ritonavir, lopinavir, atazanavir, indinavir, darunavir, the combination of tipranavir/ritonavir, etc. (medicines for AIDS),</p><p>&bull;&nbsp; some medicines used in the treatment of hepatitis C, e.g. telaprevir, boceprevir and the combination of elbasvir/grazoprevir,</p><p>&bull;&nbsp; daptomycin (a medicine used to treat complicated skin and skin structure infections and bacteraemia).</p><p>**If you need to take oral fusidic acid to treat a bacterial infection you will need to temporarily stop using this medicine. Your doctor will tell you when it is safe to restart ATOMIBE. Taking ATOMIBE with fusidic acid may rarely lead to muscle weakness, tenderness or pain (rhabdomyolysis). See more information regarding rhabdomyolysis in section 4.</p><p>&bull;&nbsp; Other medicines known to interact with ATOMIBE</p><p>&bull;&nbsp; oral contraceptives (medicines for preventing pregnancy),</p><p>&bull;&nbsp; stiripentol (an anticonvulsant medicine for epilepsy),</p><p>&bull;&nbsp; cimetidine (a medicine used for heartburn and peptic ulcers),</p><p>&bull;&nbsp; phenazone (a painkiller),</p><p>&bull;&nbsp; antacids (indigestion products containing aluminium or magnesium),</p><p>&bull;&nbsp;&nbsp; warfarin, phenprocoumon, acenocoumarol or fluindione (medicines to prevent blood clots),</p><p>&bull;&nbsp; colchicine (used to treat gout),</p><p>&bull;&nbsp; St John&#39;s wort (a medicine to treat depression).</p><p>&nbsp;</p><p>d.&nbsp;&nbsp; Taking ATOMIBE with food and drink</p><p><strong>&nbsp;</strong></p><p>See section 3 for instructions on how to take ATOMIBE. Please note the following:</p><p>&nbsp;</p><p><em>Grapefruit juice</em></p><p>Do not take more than one or two small glasses of grapefruit juice per day because large quantities of grapefruit juice can change the effects of ATOMIBE.</p><p>&nbsp;</p><p><em>Alcohol</em></p><p>Avoid drinking too much alcohol while taking this medicine. See section 2 &ldquo;Warnings and precautions&rdquo; for details.</p><p>&nbsp;</p><p>e.&nbsp;&nbsp; Fertility, Pregnancy and Lactation</p><p>Do not take ATOMIBE if you are pregnant, are trying to get pregnant or think you may be pregnant. Do not take ATOMIBE if you are able to become pregnant unless you use reliable contraceptive measures. If you get pregnant while taking ATOMIBE, stop taking it immediately and tell your doctor.</p><p>&nbsp;</p><p>Do not take ATOMIBE if you are breast-feeding.</p><p>&nbsp;</p><p>The safety of ATOMIBE during pregnancy and breast-feeding has not yet been proven.</p><p>&nbsp;</p><p>Ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p>f.&nbsp;&nbsp; Driving and using machines</p><p>ATOMIBE is not expected to interfere with your ability to drive or to use machinery. However, it should be taken into account that some people may get dizzy after taking ATOMIBE.</p><p>&nbsp;</p><p>ATOMIBE contains lactose</p><p>ATOMIBE tablets contain a sugar called lactose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.</p><p>&nbsp;</p><p>ATOMIBE contains sodium</p><p>This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Your doctor will determine the appropriate tablet strength for you, depending on your current treatment and your personal risk status. Check with your doctor or pharmacist if you are not sure.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Before starting ATOMIBE, you should be on a diet to lower your cholesterol.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You should keep on this cholesterol-lowering diet while taking ATOMIBE.</p><p>&nbsp;</p><p><u>How much to take</u></p><p>The recommended dose is one ATOMIBE tablet by mouth once a day.</p><p>&nbsp;</p><p><u>When to take</u></p><p>Take ATOMIBE at any time of the day. You can take it with or without food.</p><p>&nbsp;</p><p>If your doctor has prescribed ATOMIBE along with cholestyramine or any other bile acid sequestrant (medicines for lowering cholesterol), you should take</p><p>&nbsp;</p><p>ATOMIBE at least 2 hours before or 4 hours after taking the bile acid sequestrant.</p><p>&nbsp;</p><p>If you take more ATOMIBE than you should</p><p>Please contact your doctor or pharmacist.</p><p>&nbsp;</p><p>If you forget to take ATOMIBE</p><p>Do not take an extra dose; just take your normal amount of ATOMIBE at the usual time the next day.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>&nbsp;</strong></p><p>Like all medicines, ATOMIBE can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>If you experience any of the following serious side effects or symptoms, stop taking your tablets and tell your doctor immediately or go to the nearest hospital accident and emergency department.</p><p><strong>&nbsp;</strong></p><p>&bull;&nbsp;&nbsp; serious allergic reaction which causes swelling of the face, tongue and throat that can cause great difficulty in breathing</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp; serious illness with severe peeling and swelling of the skin, blistering of the skin, mouth, eyes genitals and fever; skin rash with pink-red blotches especially on palms of hands or soles of feet, which may blister</p><p>&nbsp;</p><p>&bull;&nbsp; muscle weakness, tenderness, pain or rupture or red-brown discolouration of urine and particularly, if at the same time, you feel unwell or have a high temperature it may be caused by an abnormal muscle breakdown which can be life-threatening and lead to kidney problems</p><p>&nbsp;</p><p>&bull;&nbsp; lupus-like disease syndrome (including rash, joint disorders and effects on blood cells)</p><p>&nbsp;</p><p>You should consult your doctor as soon as possible if you experience problems with unexpected or unusual bleeding or bruising, because this may be suggestive of a liver complaint.</p><p>&nbsp;</p><p>The following common side effects were reported (may affect up to 1 in 10 people):</p><p>&bull;&nbsp; diarrhoea,</p><p>&bull;&nbsp; muscle aches.</p><p>&nbsp;</p><p>The following uncommon side effects were reported (may affect up to 1 in 100 people):</p><p>&bull;&nbsp; the flu,</p><p>&bull;&nbsp; depression; trouble sleeping; sleep disorder,</p><p>&bull;&nbsp; dizziness; headache; tingling sensation,</p><p>&nbsp;</p><p>&bull;&nbsp; slow heartbeat,</p><p>&bull;&nbsp; hot flush,</p><p>&bull;&nbsp; shortness of breath,</p><p>&bull;&nbsp;&nbsp;&nbsp; abdominal pain; abdominal bloating; constipation; indigestion; flatulence; frequent bowel movements; inflammation of the stomach; nausea; stomach discomfort; upset stomach,</p><p>&bull;&nbsp; acne; hives,</p><p>&bull;&nbsp;&nbsp; joint pain; back pain; leg cramps; muscle fatigue, spasms, or weakness; pain in arms and legs,</p><p>&bull;&nbsp; unusual weakness; feeling tired or unwell; swelling, especially in the ankles (oedema),</p><p>&bull;&nbsp; elevations in some laboratory blood tests of liver or muscle (CK) function,</p><p>&bull;&nbsp; weight gain.</p><p>&nbsp;</p><p>Additionally, the following side effects have been reported in people taking ezetimibe or atorvastatin tablets:</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp; allergic reactions including swelling of the face, lips, tongue, and/or throat that may cause difficulty in breathing or swallowing (which requires treatment immediately),</p><p>&bull;&nbsp; raised red rash, sometimes with target-shaped lesions,</p><p>&bull;&nbsp; liver problems,</p><p>&bull;&nbsp; cough,</p><p>&bull;&nbsp; heartburn,</p><p>&bull;&nbsp; decreased appetite; loss of appetite,</p><p>&bull;&nbsp; high blood pressure,</p><p>&bull;&nbsp; skin rash and itching; allergic reactions including rash and hives,</p><p>&bull;&nbsp; tendon injury,</p><p>&bull;&nbsp;&nbsp;&nbsp; gallstones or inflammation of the gallbladder (which may cause abdominal pain, nausea, vomiting),</p><p>&bull;&nbsp; inflammation of the pancreas often with severe abdominal pain,</p><p>&bull;&nbsp; reduction in blood cell counts, which may cause bruising/bleeding (thrombocytopenia),</p><p>&bull;&nbsp; inflammation of the nasal passages; nose bleed,</p><p>&bull;&nbsp; neck pain; pain; chest pain; pain in the throat,</p><p>&bull;&nbsp; increases and decreases in blood sugar levels (if you have diabetes you should continue careful monitoring of your blood sugar levels),</p><p>&bull;&nbsp; having nightmares,</p><p>&bull;&nbsp; numbness or tingling in the fingers and toes,</p><p>&bull;&nbsp; reduction of sensation to pain or touch,</p><p>&bull;&nbsp; change in sense of taste; dry mouth,</p><p>&bull;&nbsp; loss of memory,</p><p>&bull;&nbsp; ringing in the ears and/or head; hearing loss,</p><p>&bull;&nbsp; vomiting,</p><p>&bull;&nbsp; belching,</p><p>&bull;&nbsp; hair loss,</p><p>&bull;&nbsp; raised temperature,</p><p>&bull;&nbsp; urine tests that are positive for white blood cells,</p><p>&bull;&nbsp; blurred vision; visual disturbances,</p><p>&bull;&nbsp; gynaecomastia (breast enlargement in men).</p><p>&nbsp;</p><p>Possible side effects reported with some statins</p><p>&bull;&nbsp; sexual difficulties,</p><p>&bull;&nbsp; depression,</p><p>&bull;&nbsp; breathing problems including persistent cough and/or shortness of breath or fever,</p><p>&bull;&nbsp; diabetes. This is more likely if you have high levels of sugars and fats in your blood, are overweight and have high blood pressure. Your doctor will monitor you while you are taking this medicine,</p><p>&bull;&nbsp;&nbsp; muscle pain, tenderness, or weakness that is constant and particularly if, at the same time, you feel unwell or have a high temperature that may not go away after stopping ATOMIBE (frequency not known).</p><p>&nbsp;</p><p>Reporting of side effects</p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor, health care provider or pharmacist.</p><p>&nbsp;</p><p><strong>a.&nbsp; </strong><strong>To report any side effect(s):</strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia:</strong></p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="_x0000_s1026" type="#_x0000_t202" style='position:absolute;
  margin-left:96pt;margin-top:14.8pt;width:434.25pt;height:84.85pt;z-index:-251654144;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' filled="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText style='margin-top:3.4pt;margin-right:0cm;margin-bottom:
     0cm;margin-left:23.25pt;margin-bottom:.0001pt;text-indent:-16.1pt;
     mso-list:l1 level1 lfo1;tab-stops:23.25pt 23.3pt'><![if !supportLists]><span
     style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
     Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
     </span></span></span><![endif]><span dir=LTR></span>The National
     Pharmacovigilance Centre<span style='letter-spacing:-.3pt'> </span>(NPC):<o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:12.0pt;margin-right:0cm;margin-bottom:
     0cm;margin-left:43.2pt;margin-bottom:.0001pt;text-indent:-18.05pt;
     mso-list:l1 level2 lfo1;tab-stops:43.2pt 43.25pt'><![if !supportLists]><span
     style='letter-spacing:-.1pt'><span style='mso-list:Ignore'>-<span
     style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
     dir=LTR></span>SFDA Call Center:<span style='letter-spacing:-.1pt'> </span>19999<o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:2.05pt;margin-right:0cm;margin-bottom:
     0cm;margin-left:43.2pt;margin-bottom:.0001pt;text-indent:-18.05pt;
     mso-list:l1 level2 lfo1;tab-stops:43.2pt 43.25pt'><![if !supportLists]><span
     style='letter-spacing:-.1pt'><span style='mso-list:Ignore'>-<span
     style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
     dir=LTR></span>E-mail: <a href="mailto:npc.drug@sfda.gov.sa"><span
     style='color:windowtext;text-decoration:none;text-underline:none'>npc.drug@sfda.gov.sa</span></a><o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:2.15pt;margin-right:0cm;margin-bottom:
     0cm;margin-left:43.2pt;margin-bottom:.0001pt;text-indent:-18.05pt;
     mso-list:l1 level2 lfo1;tab-stops:43.2pt 43.25pt'><![if !supportLists]><span
     style='letter-spacing:-.1pt'><span style='mso-list:Ignore'>-<span
     style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
     dir=LTR></span>Website:<span style='letter-spacing:-.05pt'> </span>https://ade.sfda.gov.sa/<o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="583" height="118" alt="Text Box: •	The National Pharmacovigilance Centre (NPC):
-	SFDA Call Center: 19999
-	E-mail: npc.drug@sfda.gov.sa
-	Website: https://ade.sfda.gov.sa/
" src="file:///C:/Users/Muhammed/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States:</strong></p><p><!--[if gte vml 1]><o:wrapblock><v:shape
  id="_x0000_s1027" type="#_x0000_t202" style='position:absolute;margin-left:91.5pt;
  margin-top:10.3pt;width:441.4pt;height:24pt;z-index:-251653120;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' filled="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText style='margin-top:3.4pt;margin-right:0cm;margin-bottom:
     0cm;margin-left:25.25pt;margin-bottom:.0001pt;tab-stops:43.25pt'>-<span
     style='mso-tab-count:1'>     </span>Please contact the relevant competent<span
     style='letter-spacing:-.05pt'> </span>authority.<o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="593" height="37" alt="Text Box: -	Please contact the relevant competent authority." src="file:///C:/Users/Muhammed/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull;&nbsp; Keep this medicine out of the sight and reach of children.</p><p>&bull;&nbsp;&nbsp;&nbsp; Do not take ATOMIBE after the expiry date stated on the carton or container after &ldquo;EXP.&rdquo; The expiry date refers to the last day of that month.</p><p>&bull;&nbsp; Store below 30&deg;C in the original package in order to protect from moisture.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>&nbsp;</strong></p><p><strong><u>Ezetimibe 10mg and Atorvastatin 10mg Film Coated Tablets</u></strong><strong> Ezetimibe 10mg</strong></p><p>Lactose monohydrate (Quantity: 126.15mg) Croscarmellose Sodium (Quantity: 16.00mg) Ezetimibe (Quantity: 10.00mg)</p><p>Polyvinyl Pyrrolidone (Quantity: 9.00mg) Sodium Lauryl sulfate (Quantity: 3.85mg) Purified Water (Quantity: q.s)</p><p>Microcrystalline Cellulose (Quantity: 32.00mg) Magnesium Stearate (Quantity: 3.00mg) <strong>Atorvastatin 10mg</strong></p><p>Atorvastatin Calcium Trihydrate equivalent to Atorvastatin (Quantity: 10.825mg of atorvastatin calcium trihydrate equivalent to 10.00mg of atorvastatin)</p><p>Lactose monohydrate (Quantity: 26.60mg) Microcrystalline cellulose (Quantity: 24.00mg) Calcium Carbonate (Quantity: 32.00mg) Croscarmellose Sodium (Quantity: 6.00mg)</p><p>&nbsp;</p><p>Hydroxy Propyl Cellulose (Quantity: 2.00mg) Polysorbate 80 (Quantity: 0.40mg)</p><p>Purified Water (Quantity: q.s)</p><p>Colloidal Anhydrous Silica (Quantity: 0.50mg) Magnesium Stearate (Quantity: 1.00mg) @Opadry-II White 31G58920 (Quantity: 4.50mg)</p><p>&nbsp;</p><p><u>Ezetimibe 10mg and Atorvastatin 20mg Film Coated Tablets</u> Ezetimibe 10mg</p><p>Lactose monohydrate (Quantity: 126.15mg) Croscarmellose Sodium (Quantity: 16.00mg) Ezetimibe (Quantity: 10.00mg)</p><p>Polyvinyl Pyrrolidone (Quantity: 9.00mg) Sodium Lauryl sulfate (Quantity: 3.85mg) Purified Water (Quantity: q.s)</p><p>Microcrystalline Cellulose (Quantity: 32.00mg) Magnesium Stearate (Quantity: 3.00mg) <strong>Atorvastatin 20mg</strong></p><p>Atorvastatin Calcium Trihydrate equivalent to Atorvastatin (Quantity: 21.65mg of atorvastatin calcium trihydrate equivalent to 20.00mg of atorvastatin)</p><p>Lactose monohydrate (Quantity: 53.20mg) Microcrystalline cellulose (Quantity: 48.00mg) Calcium Carbonate (Quantity: 64.00mg) Croscarmellose Sodium (Quantity: 12.00mg) Hydroxy Propyl Cellulose (Quantity: 4.00mg) Polysorbate 80 (Quantity: 0.80mg)</p><p>Purified Water (Quantity: q.s)</p><p>Colloidal Anhydrous Silica (Quantity: 1.00mg) Magnesium Stearate (Quantity: 2.00mg) @Opadry-II White 31G58920 (Quantity: 6.00mg)</p><p>&nbsp;</p><p><u>Ezetimibe 10mg and Atorvastatin 40mg Film Coated Tablets</u> Ezetimibe 10mg</p><p>Lactose monohydrate (Quantity: 126.15mg) Croscarmellose Sodium (Quantity: 16.00mg) Ezetimibe (Quantity: 10.00mg)</p><p>Polyvinyl Pyrrolidone (Quantity: 9.00mg) Sodium Lauryl sulfate (Quantity: 3.85mg) Purified Water (Quantity: q.s)</p><p>Microcrystalline Cellulose (Quantity: 32.00mg) Magnesium Stearate (Quantity: 3.00mg) <strong>Atorvastatin 40mg</strong></p><p>Atorvastatin Calcium Trihydrate equivalent to Atorvastatin (Quantity: 43.30mg of atorvastatin calcium trihydrate equivalent to 40.00mg of atorvastatin)</p><p>Lactose monohydrate (Quantity: 106.40mg) Microcrystalline cellulose (Quantity: 96.00mg) Calcium Carbonate (Quantity: 128.00mg) Croscarmellose Sodium (Quantity: 24.00mg)</p><p>&nbsp;</p><p>Hydroxy Propyl Cellulose (Quantity: 8.00mg) Polysorbate 80 (Quantity: 1.60mg)</p><p>Purified Water (Quantity: q.s)</p><p>Colloidal Anhydrous Silica (Quantity: 2.00mg) Magnesium Stearate (Quantity: 4.00mg) @Opadry-II White 31G58920 (Quantity: 9.00mg)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Ezetimibe 10mg and Atorvastatin 10mg Tablets
White to off white, capsule shaped, biconvex, film coated tablets with one side debossed
“1T” and other side plain.
Ezetimibe 10mg and Atorvastatin 20mg Tablets
White to off white, capsule shaped, biconvex, film coated tablets with one side debossed “2T” and other side plain.


Ezetimibe 10mg and Atorvastatin 40mg Tablets
White to off white, capsule shaped, biconvex, film coated tablets with one side debossed “4T” and other side plain.

Contents of the pack:
Available in Alu-Alu Blister pack
Alu Alu blister of 10 tablets composed of Alu Alu cold form laminate foil and Aluminium Foil. Three such blisters containing 10 tablets each are packed in a carton along with insert.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorisation Holder</p><p><strong>Saudi Amarox Industrial Company</strong></p><p>Al Jamiah Street, Al Malaz District</p><p>Riyadh 12629, Saudi Arabia</p><p>Tel &amp; Fax: +966 11 226 8850&nbsp;</p><p>&nbsp;</p><p>Manufacturer</p><p>IND-SWIFT LIMITED , India.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                d.	This leaflet was last revised in October 2022
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>اﺳم اﻟﻣﻧﺗﺞ، اﻟﻣﺎدة </strong><strong>)اﻟﻣواد</strong><strong>( اﻟﻔﻌﺎﻟﺔ وﻣﺟﻣوﻋﺔ اﻟﻌﻼج اﻟدواﺋﻲ</strong><strong>: أﺗوﻣﯾب ۰۱ ﻣﻠﺟرام </strong><strong>/ ۰۱ ﻣﻠﺟرام </strong><strong>)إزﯾﺗﻣﺎﯾب ۰۱ ﻣﻠﺟرام </strong><strong>/ أﺗورﻓﺎﺳﺗﺎﺗﯾن ۰۱ ﻣﻠﺟرام</strong><strong>(</strong></p><p dir="RTL">ﯾﺣﺗوي ﻛل ﻗرص ﻣﻐﻠف ﻋﻠﻰ أﺗورﻓﺎﺳﺗﺎﺗﯾن ۰۱ ﻣﻠﺟرام</p><p dir="RTL">إزﯾﺗﻣﺎﯾب ۰۱ ﻣﻠﺟرام</p><p dir="RTL">ﺳواﻏﺎت أﺧرى: ﻛﻣﯾﺔ ﻛﺎﻓﯾﺔ.</p><p>أﺗوﻣﯾب ۰۱ ﻣﻠﺟرام / ۰۲ ﻣﻠﺟرام )إزﯾﺗﻣﺎﯾب ۰۱ ﻣﻠﺟرام / أﺗورﻓﺎﺳﺗﺎﺗﯾن ۰۲ ﻣﻠﺟرام(</p><p dir="RTL">ﻛل ﻗرص ﻣﻐﻠف ﯾﺣﺗوي ﻋﻠﻰ أﺗورﻓﺎﺳﺗﺎﺗﯾن ۰۲ ﻣﻠﺟرام</p><p dir="RTL">إزﯾﺗﻣﺎﯾب ۰۱ ﻣﻠﺟرام</p><p dir="RTL">ﺳواﻏﺎت أﺧرى: ﻛﻣﯾﺔ ﻛﺎﻓﯾﺔ.</p><p>أﺗوﻣﯾب ۰۱ ﻣﻠﺟرام / ۰٤ ﻣﻠﺟرام )إزﯾﺗﻣﺎﯾب ۰۱ ﻣﻠﺟرام / أﺗورﻓﺎﺳﺗﺎﺗﯾن ۰٤ ﻣﻠﺟرام(</p><p dir="RTL">ﯾﺣﺗوي ﻛل ﻗرص ﻣﻐﻠف ﻋﻠﻰ أﺗورﻓﺎﺳﺗﺎﺗﯾن ۰٤ ﻣﻠﺟرام</p><p dir="RTL">إزﯾﺗﻣﺎﯾب ۰۱ ﻣﻠﺟرام</p><p dir="RTL">ﺳواﻏﺎت أﺧرى: ﻛﻣﯾﺔ ﻛﺎﻓﯾﺔ.</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">ﺳواﻏﺎت أﺧرى: ﻛﻣﯾﺔ ﻛﺎﻓﯾﺔ.</p><p dir="RTL">ﻟﻠﺣﺻول ﻋﻠﻰ اﻟﻘﺎﺋﻣﺔ اﻟﻛﺎﻣﻠﺔ ﻟﻠﺳواﻏﺎت، اﻧظر اﻟﻘﺳم ٦ )أ.(</p><p dir="RTL">ﻣﺟﻣوﻋﺔ اﻟﻌﻼج اﻟدواﺋﻲ: ﻋواﻣل ﺗﻌدﯾل ﻣﺳﺗوى اﻟدھون، ﻣﺛﺑطﺎت إﻧزﯾم H ﻣﻠﺟرام CoA -ﺑﺎﻻﺷﺗراك ﻣﻊ ﻋواﻣل أﺧرى ﻣﻌدﻟﺔ ﻟﻠدھون،</p><p>C10BA05: ATCﻛود</p><p dir="RTL">أﺗوﻣﯾب ھو ﻣﻧﺗﺞ ﺧﺎﻓض ﻟﻠدھون ﯾﻣﻧﻊ ﺑﺷﻛل اﻧﺗﻘﺎﺋﻲ اﻻﻣﺗﺻﺎص اﻟﻣﻌوي ﻟﻠﻛوﻟﯾﺳﺗرول وﺳﺗﯾروﻻت اﻟﻧﺑﺎت ذات اﻟﺻﻠﺔ وﯾﺛﺑط اﻟﺗوﻟﯾف</p><p dir="RTL">اﻟداﺧﻠﻲ ﻟﻠﻛوﻟﯾﺳﺗرول.</p><p>دواﻋﻲ اﻻﺳﺗﺧدام:</p><p dir="RTL"><u>اﻟوﻗﺎﯾﺔ ﻣن اﻷﻋراض اﻟﻘﻠﺑﯾﺔ اﻟوﻋﺎﺋﯾﺔ</u> ﯾﺗم وﺻف أﺗوﻣﯾب ﻟﻠﺣد ﻣن ﻣﺧﺎطر اﻷﻋراض اﻟﻘﻠﺑﯾﺔ اﻟوﻋﺎﺋﯾﺔ ﻓﻲ اﻟﻣرﺿﻰ اﻟذﯾن ﯾﻌﺎﻧون ﻣن أﻣراض اﻟﻘﻠب اﻟﺗﺎﺟﯾﺔ (CHD) وﺗﺎرﯾﺦ</p><p dir="RTL">ﻣﺗﻼزﻣﺔ اﻟﺷرﯾﺎن اﻟﺗﺎﺟﻲ اﻟﺣﺎدة(ACS) ، ﺳواء ﺗم ﻋﻼﺟﮭﺎ ﺳﺎﺑﻘًﺎ ﺑﺎﺳﺗﺧدام أدوﯾﺔ اﻟﺳﺗﺎﺗﯾن أم ﻻ.</p><p dir="RTL"><u>ﻓرط ﻛوﻟﯾﺳﺗرول اﻟدم</u> ﯾﺗم وﺻف أﺗوﻣﯾب ﻛﻌﻼج ﻣﺳﺎﻋد ﻟﻠﻧظﺎم اﻟﻐذاﺋﻲ ﻟﻼﺳﺗﺧدام ﻓﻲ اﻟﺑﺎﻟﻐﯾن اﻟﻣﺻﺎﺑﯾن ﺑﻔرط ﻛوﻟﯾﺳﺗرول اﻟدم اﻷوﻟﻲ )اﻟﻌﺎﺋﻠﻲ وﻏﯾر اﻟﻌﺎﺋﻠﻲ( أو</p><p dir="RTL">ﻓرط ﺷﺣﻣﯾﺎت اﻟدم اﻟﻣﺧﺗﻠط ﺣﯾث ﯾﻛون اﺳﺗﺧدام ﻣﻧﺗﺞ ﻣرﻛب ﻣﻧﺎﺳ ًﺑﺎ.</p><p dir="RTL">&middot; &nbsp;&nbsp;اﻟﻣرﺿﻰ اﻟذﯾن ﻻ ﯾﺗم اﻟﺗﺣﻛم ﺑﮭم ﺑﺷﻛل ﻣﻧﺎﺳب ﺑﺎﺳﺗﺧدام اﻟﺳﺗﺎﺗﯾن وﺣده</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; ﻣرﺿﻰ ﻋوﻟﺟوا ﺑﺳﺗﺎﺗﯾن وإزﯾﺗﻣﺎﯾب</p><p dir="RTL"><u>ﻓرط ﻛوﻟﯾﺳﺗرول اﻟدم اﻟﻌﺎﺋﻠﻲ ﻣﺗﻣﺎﺛل اﻟزﯾﺟوت</u><u>(HoFH)</u> ﯾﺗم وﺻف أﺗوﻣﯾب ﻛﻌﻼج ﻣﺳﺎﻋد ﻟﻠﻧظﺎم اﻟﻐذاﺋﻲ ﻻﺳﺗﺧداﻣﮫ ﻓﻲ اﻟﺑﺎﻟﻐﯾن اﻟﻣﺻﺎﺑﯾن ﺑﻔرط ﻛوﻟﯾﺳﺗرول اﻟدم اﻟﻌﺎﺋﻠﻲ ﻣﺗﻣﺎﺛل اﻟزﯾﺟوت</p><p dir="RTL">.(HoFH) ﻗد ﯾﺗﻠﻘﻰ اﻟﻣرﺿﻰ أﯾﺿﺎ ﻋﻼﺟﺎت ﻣﺳﺎﻋدة )ﻣﺛل ﻓﺻﺎدة اﻟﺑروﺗﯾن اﻟدھﻧﻲ ﻣﻧﺧﻔض اﻟﻛﺛﺎﻓﺔ[LDL] .(</p><p>ﻣﻌﻠوﻣﺎت ﻋن ﻓواﺋد اﺳﺗﺧدام ھذا اﻟدواء:</p><p dir="RTL">ھو دواء ﻟﺧﻔض اﻟﻣﺳﺗوﯾﺎت اﻟﻣرﺗﻔﻌﺔ ﻣن اﻟﻛوﻟﯾﺳﺗرول وﯾﺣﺗوي ﻋﻠﻰ إزﯾﺗﻣﺎﯾب وأﺗورﻓﺎﺳﺗﺎﺗﯾن.</p><p dir="RTL">ﯾﺳﺗﺧدم أﺗوﻣﯾب ﻓﻲ اﻟﺑﺎﻟﻐﯾن ﻟﺧﻔض ﻣﺳﺗوﯾﺎت اﻟﻛوﻟﯾﺳﺗرول اﻟﻛﻠﻲ واﻟﻛوﻟﯾﺳﺗرول اﻟﺿﺎر cholesterol) (LDL واﻟﻣواد اﻟدھﻧﯾﺔ اﻟﺗﻲ ﺗﺳﻣﻰ اﻟدھون اﻟﺛﻼﺛﯾﺔ ﻓﻲ اﻟدم. ﺑﺎﻹﺿﺎﻓﺔ إﻟﻰ ذﻟك، ﯾرﻓﻊ أﺗوﻣﯾب ﻣﺳﺗوﯾﺎت اﻟﻛوﻟﯾﺳﺗرول &quot;اﻟﺟﯾد&quot; )ﻛوﻟﯾﺳﺗرول اﻟﺑروﺗﯾن اﻟدھﻧﻲ ﻋﺎﻟﻲ</p><p dir="RTL">اﻟﻛﺛﺎﻓﺔ.(</p><p dir="RTL">ﯾﻌﻣل أﺗوﻣﯾب ﻋﻠﻰ ﺧﻔض ﻧﺳﺑﺔ اﻟﻛوﻟﯾﺳﺗرول ﺑطرﯾﻘﺗﯾن. إﻧﮫ ﯾﻘﻠل ﻣن ﻧﺳﺑﺔ اﻟﻛوﻟﯾﺳﺗرول اﻟﻣﻣﺗﺻﺔ ﻓﻲ ﺟﮭﺎزك اﻟﮭﺿﻣﻲ، وﻛذﻟك</p><p dir="RTL">اﻟﻛوﻟﯾﺳﺗرول اﻟذي ﯾﺻﻧﻌﮫ ﺟﺳﻣك ﻣن ﺗﻠﻘﺎء ﻧﻔﺳﮫ.</p><p dir="RTL">اﻟﻛوﻟﯾﺳﺗرول ھو أﺣد اﻟﻣواد اﻟدھﻧﯾﺔ اﻟﻌدﯾدة اﻟﻣوﺟودة ﻓﻲ ﻣﺟرى اﻟدم. ﯾﺗﻛون اﻟﻛوﻟﯾﺳﺗرول اﻟﻛﻠﻲ ﺑﺷﻛل أﺳﺎﺳﻲ ﻣن ﻛوﻟﯾﺳﺗرول اﻟﺑروﺗﯾن</p><p dir="RTL">اﻟدھﻧﻲ ﻣﻧﺧﻔض اﻟﻛﺛﺎﻓﺔ وﻛوﻟﯾﺳﺗرول اﻟﺑروﺗﯾن اﻟدھﻧﻲ ﻋﺎﻟﻲ اﻟﻛﺛﺎﻓﺔ.</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">ﻏﺎﻟﺑًﺎ ﻣﺎ طﻠﻖ ﻋﻠﻰ ﻛوﻟﯾﺳﺗرول اﻟﺑروﺗﯾن اﻟدھﻧﻲ ﻣﻧﺧﻔض اﻟﻛﺛﺎﻓﺔ (LDL) اﺳم اﻟﻛوﻟﯾﺳﺗرول &quot;اﻟﺿﺎر&quot; ﻷﻧﮫ ﯾﻣﻛن أن ﯾﺗراﻛم ﻓﻲ ﺟدران</p><p dir="RTL">اﻟﺷراﯾﯾن ﻣﻛو ًﻧﺎ طﺑﻘﺔ اﻟﺗرﺳﺑﺎت. ﯾﻣﻛن أن ﯾؤدي ﺗراﻛم ھذه اﻟﺗرﺳﺑﺎت ﻓﻲ اﻟﻧﮭﺎﯾﺔ إﻟﻰ ﺗﺿﯾﯾﻖ اﻟﺷراﯾﯾن. ﯾﻣﻛن أن ﯾؤدي ھذا اﻟﺿﯾﻖ إﻟﻰ</p><p dir="RTL">إﺑطﺎء أو ﻣﻧﻊ ﺗدﻓﻖ اﻟدم إﻟﻰ اﻷﻋﺿﺎء اﻟﺣﯾوﯾﺔ ﻣﺛل اﻟﻘﻠب واﻟدﻣﺎغ. ﯾﻣﻛن أن ﯾؤدي ﻣﻧﻊ ﺗدﻓﻖ اﻟدم إﻟﻰ ﻧوﺑﺔ ﻗﻠﺑﯾﺔ أو ﺳﻛﺗﺔ دﻣﺎﻏﯾﺔ.</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">ﻏﺎﻟﺑًﺎ ﻣﺎ طﻠﻖ ﻋﻠﻰ ﻛوﻟﯾﺳﺗرول اﻟﺑروﺗﯾن اﻟدھﻧﻲ ﻋﺎﻟﻲ اﻟﻛﺛﺎﻓﺔ (HDL) اﺳم اﻟﻛوﻟﯾﺳﺗرول &quot;اﻟﺟﯾد&quot; ﻷﻧﮫ ﯾﺳﺎﻋد ﻓﻲ ﻣﻧﻊ ﺗراﻛم اﻟﻛوﻟﯾﺳﺗرول</p><p dir="RTL">اﻟﺳﯾﺊ ﻓﻲ اﻟﺷراﯾﯾن وﯾﻘﻲ ﻣن أﻣراض اﻟﻘﻠب.</p><p dir="RTL">اﻟدھون اﻟﺛﻼﺛﯾﺔ ھﻲ ﺷﻛل آﺧر ﻣن أﺷﻛﺎل اﻟدھون ﻓﻲ اﻟدم واﻟﺗﻲ ﻗد ﺗزﯾد ﻣن ﺧطر اﻹﺻﺎﺑﺔ ﺑﺄﻣراض اﻟﻘﻠب.</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">ﯾﺳﺗﺧدم أﺗوﻣﯾب ﻟﻠﻣرﺿﻰ اﻟذﯾن ﻻ ﯾﺳﺗطﯾﻌون اﻟﺗﺣﻛم ﻓﻲ ﻣﺳﺗوﯾﺎت اﻟﻛوﻟﯾﺳﺗرول ﻋن طرﯾﻖ اﻟﻧظﺎم اﻟﻐذاﺋﻲ وﺣده. ﯾﺟب ﻋﻠﯾك اﻟﺑﻘﺎء ﻋﻠﻰ</p><p dir="RTL">ﻧظﺎم ﻏذاﺋﻲ ﻟﺧﻔض اﻟﻛوﻟﯾﺳﺗرول أﺛﻧﺎء ﺗﻧﺎول ھذا اﻟدواء.</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">ﯾﺳﺗﺧدم أﺗوﻣﯾب ﺑﺎﻹﺿﺎﻓﺔ إﻟﻰ ﻧظﺎﻣك اﻟﻐذاﺋﻲ ﻟﺧﻔض اﻟﻛوﻟﯾﺳﺗرول إذا ﻛﺎن ﻟدﯾك:</p><p dir="RTL">&middot; &nbsp;&nbsp;ارﺗﻔﺎع ﻣﺳﺗوى اﻟﻛوﻟﯾﺳﺗرول ﻓﻲ اﻟدم )ﻓرط ﻛوﻟﯾﺳﺗرول اﻟدم اﻷوﻟﻲ ]ﻣﺗﻐﺎﯾر اﻟزﯾﺟوت ﻋﺎﺋﻠﻲ وﻏﯾر ﻋﺎﺋﻠﻲ([ أو ارﺗﻔﺎع ﻣﺳﺗوﯾﺎت</p><p dir="RTL">اﻟدھون ﻓﻲ اﻟدم )ﻓرط ﺷﺣﻣﯾﺎت اﻟدم اﻟﻣﺧﺗﻠط(</p><p dir="RTL">&middot; &nbsp;&nbsp;ﻻ ﯾﺗم اﻟﺗﺣﻛم ﻓﻲ ذﻟك ﺑﺷﻛل ﺟﯾد ﺑﺎﺳﺗﺧدام أدوﯾﺔ اﻟﺳﺗﺎﺗﯾن وﺣدھﺎ. اﻟﺗﻲ اﺳﺗﺧدﻣت ﻓﯾﮭﺎ ﺳﺗﺎﺗﯾن وإزﯾﺗﻣﺎﯾب ﻛﺄﻗراص ﻣﻧﻔﺻﻠﺔ.</p><p dir="RTL">&middot; &nbsp;&nbsp;ﻣرض وراﺛﻲ )ﻓرط ﻛوﻟﯾﺳﺗرول اﻟدم اﻟﻌﺎﺋﻠﻲ ﻣﺗﻣﺎﺛل اﻟزﯾﺟوت( اﻟذي ﯾزﯾد ﻣن ﻣﺳﺗوى اﻟﻛوﻟﯾﺳﺗرول ﻓﻲ اﻟدم. ﻗد ﺗﺗﻠﻘﻰ أﯾﺿﺎ</p><p dir="RTL">ﻋﻼﺟﺎت أﺧرى.</p><p dir="RTL">&middot; &nbsp;&nbsp;ﻣرض ﻗﻠﺑﻲ. ﯾﻘﻠل أﺗوﻣﯾب ﻣن ﺧطر اﻹﺻﺎﺑﺔ ﺑﻧوﺑﺔ ﻗﻠﺑﯾﺔ أو ﺳﻛﺗﺔ دﻣﺎﻏﯾﺔ أو ﺟراﺣﺔ ﻟزﯾﺎدة ﺗدﻓﻖ اﻟدم ﻓﻲ اﻟﻘﻠب أو دﺧول</p><p dir="RTL">اﻟﻣﺳﺗﺷﻔﻰ ﻷﻟم ﻓﻲ اﻟﺻدر.</p><p dir="RTL">ﻻ ﯾﺳﺎﻋدك أﺗوﻣﯾب ﻋﻠﻰ إﻧﻘﺎص اﻟوزن.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>أ</strong><strong>.&nbsp;&nbsp;&nbsp;&nbsp; ﻻ ﺗﺳﺗﺧدم أﺗوﻣﯾب أﻗراص</strong></p><p dir="RTL">&middot; &nbsp;&nbsp;إذا ﻛﺎن ﻟدﯾك ﺣﺳﺎﺳﯾﺔ ﻣن إزﯾﺗﻣﺎﯾب / أﺗورﻓﺎﺳﺗﺎﺗﯾن أو أي ﻣن اﻟﻣﻛوﻧﺎت اﻷﺧرى ﻟﮭذا اﻟدواء )اﻟﻣدرﺟﺔ ﻓﻲ اﻟﻘﺳم ٦.(</p><p dir="RTL">&middot; &nbsp;&nbsp;إذا ﻛﺎن ﻟدﯾك أو ﺳﺑﻖ أن أﺻﺑت ﺑﻣرض ﯾﺻﯾب اﻟﻛﺑد،</p><p dir="RTL">&middot; &nbsp;&nbsp;إذا ﻛﺎن ﻟدﯾك أي اﺧﺗﺑﺎرات دم ﻏﯾر طﺑﯾﻌﯾﺔ ﻏﯾر ﻣﺑررة ﻟوظﺎﺋف اﻟﻛﺑد،</p><p dir="RTL">&middot; &nbsp;&nbsp;إذا ﻛﻧت اﻣرأة ﻗﺎدرة ﻋﻠﻰ اﻹﻧﺟﺎب وﻻ ﺗﺳﺗﺧدﻣﯾن وﺳﺎﺋل ﻣﻧﻊ ﺣﻣل ﻣوﺛوﻗﺔ،</p><p dir="RTL">&middot; &nbsp;&nbsp;&nbsp;إذا ﻛﻧت ﺣﺎﻣل، ﺗﺣﺎوﻟﯾن اﻟﺣﻣل أو ﻣرﺿﻌﺔ،</p><p dir="RTL">&middot; &nbsp;&nbsp;إذا ﻛﻧت ﺗﺳﺗﺧدم ﻣزﯾﺞ ﺟﻠﯾﻛﺎﺑرﯾﻔﯾر / ﺑﯾﺑرﻧﺗﺎﺳﻔﯾر ﻓﻲ ﻋﻼج اﻟﺗﮭﺎب اﻟﻛﺑد ﺳﻲ.</p><p>ب. &nbsp;اﻟﺗﺣذﯾرات واﻻﺣﺗﯾﺎطﺎت</p><p dir="RTL">ﺗﺣدث إﻟﻰ طﺑﯾﺑك أو اﻟﺻﯾدﻟﻲ ﻗﺑل ﺗﻧﺎول أﺗوﻣﯾب.</p><p dir="RTL">&middot; &nbsp;&nbsp;إذا ﺗﻌرﺿت ﻟﺳﻛﺗﺔ دﻣﺎﻏﯾﺔ ﺳﺎﺑﻘﺔ ﻣﺻﺣوﺑﺔ ﺑﻧزﯾف ﻓﻲ اﻟﻣﺦ، أو ﻟدﯾك ﺟﯾوب ﺻﻐﯾرة ﻣن اﻟﺳواﺋل ﻓﻲ اﻟدﻣﺎغ ﻣن ﺳﻛﺗﺎت دﻣﺎﻏﯾﺔ</p><p dir="RTL">ﺳﺎﺑﻘﺔ،</p><p dir="RTL">&middot; &nbsp;&nbsp;&nbsp;إذا ﻛﺎن ﻟدﯾك ﻣﺷﺎﻛل ﻓﻲ اﻟﻛﻠﻰ،</p><p dir="RTL">&middot; &nbsp;&nbsp;إذا ﻛﻧت ﺗﻌﺎﻧﻲ ﻣن ﻗﺻور ﻓﻲ ﻧﺷﺎط اﻟﻐدة اﻟدرﻗﯾﺔ )ﻗﺻور اﻟﻐدة اﻟدرﻗﯾﺔ(،</p><p dir="RTL">&middot; &nbsp;&nbsp;إذا ﻛﻧت ﺗﻌﺎﻧﻲ ﻣن آﻻم أو آﻻم ﻣﺗﻛررة أو ﻏﯾر ﻣﺑررة ﻓﻲ اﻟﻌﺿﻼت، أو ﻟدﯾك ﺗﺎرﯾﺦ ﺷﺧﺻﻲ أو ﺗﺎرﯾﺦ ﻋﺎﺋﻠﻲ ﻣن ﻣﺷﺎﻛل</p><p dir="RTL">اﻟﻌﺿﻼت،</p><p dir="RTL">&middot; &nbsp;&nbsp;إذا ﻋﺎﻧﯾت ﺳﺎﺑﻘًﺎ ﻣن ﻣﺷﺎﻛل ﻋﺿﻠﯾﺔ أﺛﻧﺎء اﻟﻌﻼج ﺑﺄدوﯾﺔ أﺧرى ﺧﺎﻓﺿﺔ ﻟﻠدھون )ﻋﻠﻰ ﺳﺑﯾل اﻟﻣﺛﺎل أدوﯾﺔ &quot;اﻟﺳﺗﺎﺗﯾن&quot; أو</p><p dir="RTL">&quot;اﻟﻔﺎﯾﺑرات&quot; اﻷﺧرى(،</p><p dir="RTL">&middot; &nbsp;&nbsp;إذا ﻛﻧت ﺗﺷرب ﻛﻣﯾﺔ ﻛﺑﯾرة ﻣن اﻟﻛﺣول ﺑﺎﻧﺗظﺎم،</p><p dir="RTL">&middot; &nbsp;&nbsp;إذا ﻛﺎن ﻟدﯾك ﺗﺎرﯾﺦ ﻣن أﻣراض اﻟﻛﺑد.</p><p dir="RTL">&middot; &nbsp;&nbsp;&nbsp;إذا ﻛﺎن ﻋﻣرك أﻛﺑر ﻣن ۰۷ ﻋﺎﻣﺎ،</p><p dir="RTL">&middot; &nbsp;&nbsp;إذا أﺧﺑرك طﺑﯾﺑك ﺑﺄﻧك ﻻ ﺗﺗﺣﻣل ﺑﻌض اﻟﺳﻛرﯾﺎت، اﺗﺻل ﺑطﺑﯾﺑك ﻗﺑل ﺗﻧﺎول ھذا اﻟﻣﻧﺗﺞ،</p><p dir="RTL">&middot; &nbsp;&nbsp;إذا ﻛﻧت ﺗﺗﻧﺎول أو ﺗﻧﺎوﻟت ﻓﻲ اﻷﯾﺎم اﻟﺳﺑﻌﺔ اﻟﻣﺎﺿﯾﺔ دواء ﯾﺳﻣﻰ ﺣﻣض اﻟﻔﯾوﺳﯾدﯾك )دواء ﻟﻠﻌدوى اﻟﺑﻛﺗﯾرﯾﺔ( ﻋن طرﯾﻖ اﻟﻔم أو</p><p dir="RTL">ﻋن طرﯾﻖ اﻟﺣﻘن. ﯾﻣﻛن أن ﯾؤدي اﻟﺟﻣﻊ ﺑﯾن ﺣﻣض اﻟﻔﯾوﺳﯾدﯾك وأﺗوﻣﯾب إﻟﻰ ﻣﺷﺎﻛل ﻋﺿﻠﯾﺔ ﺧطﯾرة )اﻧﺣﻼل اﻟرﺑﯾدات.(</p><p dir="RTL">اﺗﺻل ﺑطﺑﯾﺑك ﻋﻠﻰ اﻟﻔور إذا ﻛﻧت ﺗﻌﺎﻧﻲ ﻣن أﻟم ﻋﺿﻠﻲ ﻏﯾر ﻣﺑرر أو رﻗﺔ أو ﺿﻌف أﺛﻧﺎء ﺗﻧﺎول أﺗوﻣﯾب. ھذا ﻷﻧﮫ ﻓﻲ ﺣﺎﻻت ﻧﺎدرة، ﯾﻣﻛن أن ﺗﻛون ﻣﺷﺎﻛل اﻟﻌﺿﻼت ﺧطﯾرة، ﺑﻣﺎ ﻓﻲ ذﻟك اﻧﮭﯾﺎر اﻟﻌﺿﻼت ﻣﻣﺎ ﯾؤدي إﻟﻰ ﺗﻠف اﻟﻛﻠﻰ. ﻣن اﻟﻣﻌروف أن أﺗورﻓﺎﺳﺗﺎﺗﯾن ﯾﺳﺑب ﻣﺷﺎﻛل</p><p dir="RTL">ﻓﻲ اﻟﻌﺿﻼت، ﻛﻣﺎ ﺗم اﻹﺑﻼغ ﻋن ﺣﺎﻻت ﻣﺷﺎﻛل ﻋﺿﻠﯾﺔ ﺑﺳﺑب إزﯾﺗﻣﺎﯾب.</p><p>&nbsp;</p><p dir="RTL">ﺿﺎ إذا ﻛﻧت ﺗﻌﺎﻧﻲ ﻣن ﺿﻌف ﻋﺿﻠﻲ ﻣﺳﺗﻣر. ﻗد ﺗﻛون ھﻧﺎك ﺣﺎﺟﺔ ﻻﺧﺗﺑﺎرات وأدوﯾﺔ إﺿﺎﻓﯾﺔ ﻟﺗﺷﺧﯾص</p><p>&nbsp;</p><p dir="RTL">أﺧﺑر طﺑﯾﺑك أو اﻟﺻﯾدﻟﻲ أﯾ</p><p dir="RTL">وﻋﻼج ھذا.</p><p>&nbsp;</p><p dir="RTL">اﺳﺗﺷر طﺑﯾﺑك أو اﻟﺻﯾدﻟﻲ ﻗﺑل ﺗﻧﺎول أﺗوﻣﯾب</p><p dir="RTL">&middot; &nbsp;&nbsp;إذا ﻛﺎن ﻟدﯾك ﻗﺻور ﺣﺎد ﻓﻲ اﻟﺟﮭﺎز اﻟﺗﻧﻔﺳﻲ.</p><p dir="RTL">إذا ﻛﺎﻧت أي ﻣن ھذه ﺗﻧطﺑﻖ ﻋﻠﯾك )أو ﻟم ﺗﻛن ﻣﺗﺄﻛدا(، ﺗﺣدث إﻟﻰ طﺑﯾﺑك أو اﻟﺻﯾدﻟﻲ ﻗﺑل ﺗﻧﺎول أﺗوﻣﯾب ﻷن طﺑﯾﺑك ﺳﯾﺣﺗﺎج إﻟﻰ إﺟراء ﻓﺣص دم ﻗﺑل ورﺑﻣﺎ أﺛﻧﺎء اﻟﻌﻼج ﺑﺎﺳﺗﺧدام أﺗوﻣﯾب ﻟﻠﺗﻧﺑؤ ﺑﺧطر اﻹﺻﺎﺑﺔ ﺑﺎﻟﻌﺿﻼت. آﺛﺎر ﺟﺎﻧﺑﯾﺔ. ﻣﺧﺎطر اﻵﺛﺎر اﻟﺟﺎﻧﺑﯾﺔ اﻟﻣرﺗﺑطﺔ ﺑﺎﻟﻌﺿﻼت، ﻋﻠﻰ ﺳﺑﯾل اﻟﻣﺛﺎل ﻣن اﻟﻣﻌروف أن اﻧﺣﻼل اﻟرﺑﯾدات ﯾزداد ﻋﻧد ﺗﻧﺎول ﺑﻌض اﻷدوﯾﺔ ﻓﻲ ﻧﻔس اﻟوﻗت )اﻧظر اﻟﻘﺳم ۲ &quot;أدوﯾﺔ</p><p dir="RTL">أﺧرى وأﺗوﻣﯾب.(&quot;</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">أﺛﻧﺎء ﺗﻧﺎوﻟك ﻟﮭذا اﻟدواء، ﺳﯾراﻗﺑك طﺑﯾﺑك ﻋن ﻛﺛب إذا ﻛﻧت ﻣﺻﺎ ًﺑﺎ ﺑﻣرض اﻟﺳﻛري أو ﻣﻌرض ﻟﻺﺻﺎﺑﺔ ﺑﻣرض اﻟﺳﻛري. ﻣن اﻟﻣﺣﺗﻣل أن</p><p>&nbsp;</p><p dir="RTL">ﺿﺎ ﻟﺧطر اﻹﺻﺎﺑﺔ ﺑﻣرض اﻟﺳﻛري إذا ﻛﺎن ﻟدﯾك ﻣﺳﺗوﯾﺎت ﻋﺎﻟﯾﺔ ﻣن اﻟﺳﻛرﯾﺎت واﻟدھون ﻓﻲ دﻣك، وزﯾﺎدة اﻟوزن وارﺗﻔﺎع</p><p>&nbsp;</p><p dir="RTL">ﺗﻛون ﻣﻌر</p><p dir="RTL">ﺿﻐط اﻟدم.</p><p>&nbsp;</p><p dir="RTL">أﺧﺑر طﺑﯾﺑك ﻋن ﺟﻣﯾﻊ ﺣﺎﻻﺗك اﻟطﺑﯾﺔ ﺑﻣﺎ ﻓﻲ ذﻟك اﻟﺣﺳﺎﺳﯾﺔ. ﯾﺟب ﺗﺟﻧب اﻻﺳﺗﺧدام اﻟﻣﺷﺗرك أﺗوﻣﯾب واﻟﻔﺎﯾﺑرات )أدوﯾﺔ ﻟﺧﻔض اﻟﻛوﻟﯾﺳﺗرول( ﺣﯾث ﻟم ﯾﺗم دراﺳﺔ اﻻﺳﺗﺧدام اﻟﻣﺷﺗرك أﺗوﻣﯾب</p><p dir="RTL">واﻟﻔﺎﯾﺑرات.</p><p>اﻷطﻔﺎل</p><p dir="RTL">ﻻ ﯾﻧﺻﺢ ﺑﺎﺳﺗﺧدام أﺗوﻣﯾب ﻟﻸطﻔﺎل واﻟﻣراھﻘﯾن.</p><p>ت. &nbsp;ﺗﻧﺎول أو اﺳﺗﺧدام أدوﯾﺔ أﺧرى أو أﻋﺷﺎب أو ﻣﻛﻣﻼت ﻏذاﺋﯾﺔ</p><p dir="RTL">أﺧﺑر طﺑﯾﺑك أو اﻟﺻﯾدﻟﻲ إذا ﻛﻧت ﺗﺗﻧﺎول، أو ﺗﻧﺎوﻟت ﻣؤﺧ&nbsp; ًرا،&nbsp;أو ﻗد ﺗﺗﻧﺎول أي دواء آﺧر</p><p dir="RTL">ھﻧﺎك ﺑﻌض اﻷدوﯾﺔ اﻟﺗﻲ ﻗد ﺗﻐﯾر ﺗﺄﺛﯾر أﺗوﻣﯾب أو ﻗد ﯾﺗﻐﯾر ﺗﺄﺛﯾرھﺎ ﺑواﺳطﺔ أﺗوﻣﯾب )اﻧظر اﻟﻘﺳم ۳.( ھذا اﻟﻧوع ﻣن اﻟﺗﻔﺎﻋل ﯾﻣﻛن أن ﯾﺟﻌل أﺣد اﻷدوﯾﺔ أو ﻛﻠﯾﮭﻣﺎ أﻗل ﻓﻌﺎﻟﯾﺔ. ﺑدﻻً&nbsp;ﻣن ذﻟك، ﯾﻣﻛن أن ﯾزﯾد ﻣن ﺧطر أو ﺷدة اﻵﺛﺎر اﻟﺟﺎﻧﺑﯾﺔ، ﺑﻣﺎ ﻓﻲ ذﻟك ﺣﺎﻟﺔ ﺿﻌف اﻟﻌﺿﻼت اﻟﻣﮭﻣﺔ</p><p dir="RTL">اﻟﻣﻌروﻓﺔ ﺑﺎﺳم &quot;اﻧﺣﻼل اﻟرﺑﯾدات&quot; اﻟﻣوﺻوف ﻓﻲ اﻟﻘﺳم ٤:</p><p dir="RTL">&middot; &nbsp;&nbsp;&nbsp;اﻟﺳﯾﻛﻠوﺳﺑورﯾن )دواء ﯾﺳﺗﺧدم ﻏﺎﻟ ًﺑﺎ ﻓﻲ ﻣرﺿﻰ زراﻋﺔ اﻷﻋﺿﺎء(،</p><p dir="RTL">&middot; &nbsp;&nbsp;إرﯾﺛروﻣﯾﺳﯾن، ﻛﻼرﯾﺛروﻣﯾﺳﯾن، ﺗﯾﻠﯾﺛروﻣﯾﺳﯾن، ﺣﻣض اﻟﻔﯾوﺳﯾدﯾك **، رﯾﻔﺎﻣﺑﯾﺳﯾن )أدوﯾﺔ ﻟﻠﻌدوى اﻟﺑﻛﺗﯾرﯾﺔ(،</p><p dir="RTL">&middot; &nbsp;&nbsp;ﻛﯾﺗوﻛوﻧﺎزول، إﯾﺗراﻛوﻧﺎزول، ﻓورﯾﻛوﻧﺎزول، ﻓﻠوﻛوﻧﺎزول، ﺑوﺳﺎﻛوﻧﺎزول )أدوﯾﺔ ﻟﻠﻌدوى اﻟﻔطرﯾﺔ(،</p><p dir="RTL">&middot; &nbsp;&nbsp;ﺟﻣﻔﺑروزﯾل، ﻓﯾﺑرات أﺧرى، ﺣﻣض اﻟﻧﯾﻛوﺗﯾن، ﻣﺷﺗﻘﺎﺗﮫ، ﻛوﻟﯾﺳﺗﯾﺑول، ﻛوﻟﯾﺳﺗراﻣﯾن )أدوﯾﺔ ﻟﺗﻧظﯾم ﻣﺳﺗوﯾﺎت اﻟدھون(،</p><p dir="RTL">&middot; &nbsp;&nbsp;ﺑﻌض ﺣﺎﺻرات ﻗﻧوات اﻟﻛﺎﻟﺳﯾوم اﻟﻣﺳﺗﺧدﻣﺔ ﻓﻲ اﻟذﺑﺣﺔ اﻟﺻدرﯾﺔ أو ارﺗﻔﺎع ﺿﻐط اﻟدم، ﻋﻠﻰ ﺳﺑﯾل اﻟﻣﺛﺎل أﻣﻠودﯾﺑﯾن، دﯾﻠﺗﯾﺎزﯾم،</p><p dir="RTL">&middot; &nbsp;&nbsp;دﯾﺟوﻛﺳﯾن، ﻓﯾراﺑﺎﻣﯾل، أﻣﯾودارون )أدوﯾﺔ ﻟﺗﻧظﯾم ﺿرﺑﺎت اﻟﻘﻠب.(</p><p dir="RTL">&middot; &nbsp;&nbsp;اﻷدوﯾﺔ اﻟﻣﺳﺗﺧدﻣﺔ ﻓﻲ ﻋﻼج ﻓﯾروس ﻧﻘص اﻟﻣﻧﺎﻋﺔ اﻟﺑﺷرﯾﺔ، ﻋﻠﻰ ﺳﺑﯾل اﻟﻣﺛﺎل. رﯾﺗوﻧﺎﻓﯾر، ﻟوﺑﯾﻧﺎﻓﯾر، أﺗﺎزاﻧﺎﻓﯾر، إﻧدﯾﻧﺎﻓﯾر،</p><p dir="RTL">داروﻧﺎﻓﯾر، ﻣزﯾﺞ ﻣن ﺗﯾﺑراﻧﺎﻓﯾر / رﯾﺗوﻧﺎﻓﯾر، إﻟﺦ )أدوﯾﺔ اﻹﯾدز(،</p><p dir="RTL">&middot; &nbsp;&nbsp;ﺑﻌض اﻷدوﯾﺔ اﻟﻣﺳﺗﺧدﻣﺔ ﻓﻲ ﻋﻼج اﻟﺗﮭﺎب اﻟﻛﺑد ﺳﻲ، ﻋﻠﻰ ﺳﺑﯾل اﻟﻣﺛﺎل. ﺗﯾﻼﺑرﯾﻔﯾرو ﺑوﺳﺑرﯾﻔﯾروﻣزﯾﺞ ﻣن إﻟﺑﺎﺳﻔﯾر /</p><p dir="RTL">ﺟرازوﺑرﯾﯾﻔﯾر،</p><p dir="RTL">&middot; &nbsp;&nbsp;داﺑﺗوﻣﺎﯾﺳﯾن )دواء ﯾﺳﺗﺧدم ﻟﻌﻼج اﻟﺗﮭﺎﺑﺎت اﻟﺟﻠد واﻟﺑﻧﯾﺔ اﻟﻣﻌﻘدة وﺗﺟرﺛم اﻟدم.(</p><p dir="RTL">**إذا ﻛﻧت ﺑﺣﺎﺟﺔ إﻟﻰ ﺗﻧﺎول ﺣﻣض اﻟﻔﯾوﺳﯾدﯾك ﻋن طرﯾﻖ اﻟﻔم ﻟﻌﻼج ﻋدوى ﺑﻛﺗﯾرﯾﺔ، ﻓﺳﺗﺣﺗﺎج إﻟﻰ اﻟﺗوﻗف ﻋن اﺳﺗﺧدام ھذا اﻟدواء ﻣؤﻗﺗًﺎ. ﺳﯾﺧﺑرك طﺑﯾﺑك ﻋﻧدﻣﺎ ﯾﻛون ﻣن اﻵﻣن إﻋﺎدة اﺳﺗﺧدام أﺗوﻣﯾب.&nbsp;ﻧﺎد&nbsp;ًرا&nbsp;ﻣﺎ ﯾؤدي ﺗﻧﺎول أﺗوﻣﯾب ﻣﻊ ﺣﻣض اﻟﻔﯾوﺳﯾدﯾك إﻟﻰ ﺿﻌف اﻟﻌﺿﻼت</p><p dir="RTL">أو إﯾﻼﻣﮭﺎ أو أﻟﻣﮭﺎ )اﻧﺣﻼل اﻟرﺑﯾدات.( اﻧظر اﻟﻣزﯾد ﻣن اﻟﻣﻌﻠوﻣﺎت ﺣول اﻧﺣﻼل اﻟرﺑﯾدات ﻓﻲ اﻟﻘﺳم ٤.</p><p dir="RTL">&middot; &nbsp;&nbsp;&nbsp;اﻷدوﯾﺔ اﻷﺧرى اﻟﻣﻌروﻓﺔ ﺑﺗﻔﺎﻋﻠﮭﺎ ﻣﻊ أﺗوﻣﯾب</p><p dir="RTL">&middot; &nbsp;&nbsp;&nbsp;ﻣواﻧﻊ اﻟﺣﻣل اﻟﻔﻣوﯾﺔ )أدوﯾﺔ ﻟﻣﻧﻊ اﻟﺣﻣل(،</p><p dir="RTL">&middot; &nbsp;&nbsp;&nbsp;ﺳﺗرﯾﺑﯾﻧﺗول )دواء ﻣﺿﺎد ﻟﻠﺻرع(،</p><p dir="RTL">&middot; &nbsp;&nbsp;ﺳﯾﻣﯾﺗﯾدﯾن )دواء ﯾﺳﺗﺧدم ﻟﺣرﻗﺔ اﻟﻣﻌدة واﻟﻘرﺣﺔ اﻟﮭﺿﻣﯾﺔ.(</p><p dir="RTL">&middot; &nbsp;&nbsp;&nbsp;ﻓﯾﻧﺎزون )ﻣﺳﻛن ﻟﻸﻟم(،</p><p dir="RTL">&middot; &nbsp;&nbsp;ﻣﺿﺎدات اﻟﺣﻣوﺿﺔ )ﻣﻧﺗﺟﺎت ﻋﺳر اﻟﮭﺿم اﻟﺗﻲ ﺗﺣﺗوي ﻋﻠﻰ اﻷﻟوﻣﻧﯾوم أو اﻟﻣﻐﻧﯾﺳﯾوم(،</p><p dir="RTL">&middot; &nbsp;&nbsp;اﻟوارﻓﺎرﯾن، اﻟﻔﯾﻧﺑروﻛوﻣون، أﺳﯾﻧوﻛوﻣﺎرول أو ﻓﻠوﯾﻧدﯾون )أدوﯾﺔ ﻟﻣﻧﻊ ﺗﺟﻠط اﻟدم.(</p><p dir="RTL">&middot; &nbsp;&nbsp;&nbsp;اﻟﻛوﻟﺷﯾﺳﯾن )ﯾﺳﺗﺧدم ﻟﻌﻼج اﻟﻧﻘرس.(</p><p dir="RTL">&middot; &nbsp;&nbsp;ﻧﺑﺗﺔ ﺳﺎﻧت ﺟون )دواء ﻟﻌﻼج اﻻﻛﺗﺋﺎب.(</p><p>ث. &nbsp;ﺗﻧﺎول أﺗوﻣﯾب ﻣﻊ اﻟطﻌﺎم واﻟﺷراب</p><p dir="RTL">اﻧظر اﻟﻘﺳم ۳ ﻟﻠﺣﺻول ﻋﻠﻰ ﺗﻌﻠﯾﻣﺎت ﺣول ﻛﯾﻔﯾﺔ ﺗﻧﺎول أﺗوﻣﯾب. ﯾرﺟﻰ ﻣﻼﺣظﺔ ﻣﺎ ﯾﻠﻲ:</p><p>ﻋﺻﯾر ﺟرﯾب ﻓروت</p><p dir="RTL">ﻻ ﺗﺗﻧﺎول أﻛﺛر ﻣن ﻛوب أو ﻛوﺑﯾن ﻣن ﻋﺻﯾر اﻟﺟرﯾب ﻓروت ﯾوﻣ ًﯾﺎ ﻷن اﻟﻛﻣﯾﺎت اﻟﻛﺑﯾرة ﻣن ﻋﺻﯾر اﻟﺟرﯾب ﻓروت ﯾﻣﻛن أن ﺗﻐﯾر ﺗﺄﺛﯾر</p><p dir="RTL">أﺗوﻣﯾب.</p><p>اﻟﻛﺣول</p><p>&nbsp;</p><p><em>&nbsp;</em></p><p dir="RTL">ﺗﺟﻧب ﺷرب اﻟﻛﺛﯾر ﻣن اﻟﻛﺣول أﺛﻧﺎء ﺗﻧﺎول ھذا اﻟدواء. اﻧظر اﻟﻘﺳم ۲ &quot;اﻟﺗﺣذﯾرات واﻻﺣﺗﯾﺎطﺎت&quot; ﻟﻠﺣﺻول ﻋﻠﻰ اﻟﺗﻔﺎﺻﯾل.</p><p>ج. &nbsp;اﻟﺧﺻوﺑﺔ واﻟﺣﻣل واﻟرﺿﺎﻋﺔ</p><p>&nbsp;</p><p dir="RTL">ت ﻗﺎدرة ﻋﻠﻰ اﻟﺣﻣل إﻻ إذا</p><p>&nbsp;</p><p dir="RTL">ﯾﺟب ﻋدم اﺳﺗﺧدام أﺗوﻣﯾب إذا ﻛﻧت ﺣﺎﻣﻼً&nbsp;أو ﺗﺣﺎوﻟﯾن اﻟﺣﻣل أو ﺗﻌﺗﻘدﯾن أﻧك ﺣﺎﻣل. ﻻ ﺗﺗﻧﺎوﻟﻲ أﺗوﻣﯾب إذا ﻛﻧ</p><p>&nbsp;</p><p dir="RTL">ﻛﻧت ﺗﺳﺗﺧدﻣﯾن وﺳﺎﺋل ﻣﻧﻊ ﺣﻣل ﻣوﺛوﻗﺔ. إذا ﺣﻣﻠت أﺛﻧﺎء ﺗﻧﺎول أﺗوﻣﯾب، ﻓﺗوﻗﻔﻲ ﻋن ﺗﻧﺎوﻟﮫ ﻋﻠﻰ اﻟﻔور وأﺧﺑري طﺑﯾﺑك.</p><p dir="RTL">ﻻ ﺗﺗﻧﺎوﻟﻲ أﺗوﻣﯾب إذا ﻛﻧت ﻣرﺿﻌﺔ.</p><p dir="RTL">ﻟم ﯾﺗم ﺑﻌد إﺛﺑﺎت ﺳﻼﻣﺔ أﺗوﻣﯾب أﺛﻧﺎء اﻟﺣﻣل واﻟرﺿﺎﻋﺔ.</p><p dir="RTL">اﺳﺄل طﺑﯾﺑك أو اﻟﺻﯾدﻟﻲ ﻟﻠﺣﺻول ﻋﻠﻰ اﻟﻣﺷورة ﻗﺑل ﺗﻧﺎول ھذا اﻟدواء.</p><p>ح. &nbsp;اﻟﻘﯾﺎدة واﺳﺗﺧدام اﻵﻻت</p><p dir="RTL">ﻟﯾس ﻣن اﻟﻣﺗوﻗﻊ أن ﯾﺗﻌﺎرض أﺗوﻣﯾب ﻣﻊ ﻗدرﺗك ﻋﻠﻰ اﻟﻘﯾﺎدة أو اﺳﺗﺧدام اﻵﻻت. وﻣﻊ ذﻟك، ﯾﺟب أن ﯾؤﺧذ ﻓﻲ اﻻﻋﺗﺑﺎر أن ﺑﻌض</p><p dir="RTL">اﻷﺷﺧﺎص ﻗد ﯾﺻﺎﺑون ﺑﺎﻟدوار ﺑﻌد ﺗﻧﺎول أﺗوﻣﯾب.</p><p>ﻣﺣﺗوي أﺗوﻣﯾب ﻣن اﻟﻼﻛﺗوز</p><p dir="RTL">ﺗﺣﺗوي أﻗراص أﺗوﻣﯾب ﻋﻠﻰ ﺳﻛر ﯾﺳﻣﻰ اﻟﻼﻛﺗوز. إذا أﺧﺑرك طﺑﯾﺑك أن ﻟدﯾك ﺣﺳﺎﺳﯾﺔ ﺗﺟﺎه ﺑﻌض اﻟﺳﻛرﯾﺎت، ﻓﺎﺗﺻل ﺑطﺑﯾﺑك ﻗﺑل ﺗﻧﺎول</p><p dir="RTL">ھذا اﻟﻣﻧﺗﺞ اﻟطﺑﻲ.</p><p>ﻣﺣﺗوي أﺗوﻣﯾب ﻣن اﻟﺻودﯾوم</p><p dir="RTL">ﯾﺣﺗوي ھذا اﻟدواء ﻋﻠﻰ أﻗل ﻣن ۱ ﻣﻠﯾﻣول ﺻودﯾوم )۳۲ ﻣﻠﺟرام( ﻟﻛل ﻗرص، وھذا ﯾﻌﻧﻲ ﺑﺷﻛل أﺳﺎﺳﻲ &quot;ﺧﺎ&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ٍل ﻣن اﻟﺻودﯾوم.&quot;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احرص دائمًا على تناول هذا الدواء تمامًا كما أخبرك طبيبك. سيحدد طبيبك تركيز الأقراص المناسبة لك، اعتمادًا على علاجك الحالي وحالة المخاطر الشخصية الخاصة بك. استشر طبيبك أو الصيدلي إذا لم تكن متأكدًا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قبل البدء في تناول أتومیب، يجب أن تتبع نظامًا غذائيًا لخفض نسبة الكوليسترول لديك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب أن تحافظ على هذا النظام الغذائي المخفض للكوليسترول أثناء تناول أتومیب.</p><p dir="RTL"><strong>الجرعة</strong></p><p dir="RTL">الجرعة الموصى بها هي قرص واحد من أتومیب عن طريق الفم مرة واحدة في اليوم.</p><p dir="RTL"><strong>متى ينبغي تناول الجرعة</strong></p><p dir="RTL">تناول أتومیب في أي وقت من اليوم. تستطيع ان تتناوله مع الأكل او من غير الأكل.</p><p dir="RTL">إذا وصف طبيبك أتومیب جنبًا إلى جنب مع الكوليسترامين أو أي مادة أخرى من منحيات حامض الصفراء (أدوية لخفض الكوليسترول)، يجب أن تتناول أتومیب قبل ساعتين على الأقل أو بعد 4 ساعات من تناول منحيات حامض الصفراء.</p><p dir="RTL"><strong>تناول جرعة زائدة من أتومیب أقراص</strong></p><p dir="RTL">الرجاء الاتصال بطبيبك أو الصيدلي.</p><p dir="RTL"><strong>إذا نسيت أن تتناول أتومیب</strong></p><p dir="RTL">لا تتناول جرعة إضافية. فقط تناول كمية أتومیب العادية في الوقت المعتاد في اليوم التالي.</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء، اسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ﻣﺛل ﺟﻣﯾﻊ اﻷدوﯾﺔ، ﯾﻣﻛن أن ﯾﺳﺑب أﺗوﻣﯾب آﺛﺎ&nbsp;ًرا&nbsp;ﺟﺎﻧﺑﯾﺔ، ﻋﻠﻰ اﻟرﻏم ﻣن ﻋدم ﺣدوﺛﮭﺎ ﻟدى اﻟﺟﻣﯾﻊ.&nbsp;إذا واﺟﮭت أ ًﯾﺎ ﻣن اﻷﻋراض اﻟﺟﺎﻧﺑﯾﺔ اﻟﺧطﯾرة اﻟﺗﺎﻟﯾﺔ، ﻓﺗوﻗف ﻋن ﺗﻧﺎول أﻗراﺻك وأﺧﺑر طﺑﯾﺑك ﻋﻠﻰ اﻟﻔور أو اذھب إﻟﻰ أﻗرب ﻗﺳم</p><p dir="RTL">ﻟﻠﺣوادث واﻟطوارئ ﻓﻲ اﻟﻣﺳﺗﺷﻔﻰ.</p><p dir="RTL">&middot; &nbsp;&nbsp;رد ﻓﻌل ﺗﺣﺳﺳﻲ ﺧطﯾر ﯾﺳﺑب اﻧﺗﻔﺎخ اﻟوﺟﮫ واﻟﻠﺳﺎن واﻟﺣﻠﻖ ﻣﻣﺎ ﯾﺳﺑب ﺻﻌوﺑﺔ ﻛﺑﯾرة ﻓﻲ اﻟﺗﻧﻔس</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">&middot; &nbsp;&nbsp;ﻣرض ﺧطﯾر ﻣﺻﺣوب ﺑﺗﻘﺷﯾر ﺷدﯾد واﻧﺗﻔﺎخ ﻓﻲ اﻟﺟﻠد وﺑﺛور ﻓﻲ اﻟﺟﻠد واﻟﻔم واﻟﻌﯾﻧﯾن واﻷﻋﺿﺎء اﻟﺗﻧﺎﺳﻠﯾﺔ واﻟﺣﻣﻰ. طﻔﺢ ﺟﻠدي</p><p dir="RTL">ﻣﺻﺣوب ﺑﺑﻘﻊ وردﯾﺔ-ﺣﻣراء ﺧﺎﺻﺔ ﻋﻠﻰ راﺣﺗﻲ اﻟﯾدﯾن أو ﺑﺎطن اﻟﻘدﻣﯾن، واﻟﺗﻲ ﻗد ﺗﻧﻔﺦ</p><p dir="RTL">&middot; &nbsp;&nbsp;ﺿﻌف اﻟﻌﺿﻼت، أو إﯾﻼﻣﮭﺎ، أو أﻟﻣﮭﺎ، أو ﺗﻣزﻗﮭﺎ، أو ﺗﻐﯾر ﻟون اﻟﺑول إﻟﻰ اﻟﻠون اﻷﺣﻣر إﻟﻰ اﻟﺑﻧﻲ، وﻋﻠﻰ وﺟﮫ اﻟﺧﺻوص، إذا</p><p dir="RTL">ﺷﻌرت ﻓﻲ ﻧﻔس اﻟوﻗت ﺑﺗوﻋك أو ارﺗﻔﺎع ﻓﻲ درﺟﺔ اﻟﺣرارة، ﻓﻘد ﯾﻛون ﺳﺑب ذﻟك ھو اﻧﮭﯾﺎر ﻋﺿﻠﻲ ﻏﯾر طﺑﯾﻌﻲ ﯾﻣﻛن أن ﯾﮭدد</p><p dir="RTL">اﻟﺣﯾﺎة وﯾؤدي إﻟﻰ ﻟﻣﺷﺎﻛل اﻟﻛﻠﻰ</p><p dir="RTL">&middot; &nbsp;&nbsp;ﻣﺗﻼزﻣﺔ اﻟﻣرض اﻟﺷﺑﯾﮫ ﺑﻣرض اﻟذﺋﺑﺔ )ﺑﻣﺎ ﻓﻲ ذﻟك اﻟطﻔﺢ اﻟﺟﻠدي واﺿطراﺑﺎت اﻟﻣﻔﺎﺻل وﺗﺄﺛﯾراﺗﮭﺎ ﻋﻠﻰ ﺧﻼﯾﺎ اﻟدم(</p><p dir="RTL">ﯾﺟب ﻋﻠﯾك اﺳﺗﺷﺎرة طﺑﯾﺑك ﻓﻲ أﻗرب وﻗت ﻣﻣﻛن إذا واﺟﮭت ﻣﺷﺎﻛل ﻣﻊ ﻧزﯾف ﻏﯾر ﻣﺗوﻗﻊ أو ﻏﯾر ﻋﺎدي أو ﻛدﻣﺎت، ﻷن ھذا ﻗد ﯾﺷﯾر إﻟﻰ</p><p dir="RTL">ﺷﻛوى ﻣن اﻟﻛﺑد.</p><p dir="RTL">ﺗم اﻹﺑﻼغ ﻋن اﻵﺛﺎر اﻟﺟﺎﻧﺑﯾﺔ اﻟﺷﺎﺋﻌﺔ اﻟﺗﺎﻟﯾﺔ )ﻗد ﺗؤﺛر ﻋﻠﻰ ﻣﺎ ﯾﺻل إﻟﻰ ۱ ﻣن ﻛل ۰۱ أﺷﺧﺎص:(</p><p dir="RTL">&middot; &nbsp;&nbsp;&nbsp;إﺳﮭﺎل،</p><p dir="RTL">&middot; &nbsp;&nbsp;&nbsp;آﻻم اﻟﻌﺿﻼت.</p><p dir="RTL">ﺗم اﻹﺑﻼغ ﻋن اﻵﺛﺎر اﻟﺟﺎﻧﺑﯾﺔ ﻏﯾر اﻟﺷﺎﺋﻌﺔ اﻟﺗﺎﻟﯾﺔ )ﻗد ﺗؤﺛر ﻋﻠﻰ ﻣﺎ ﯾﺻل إﻟﻰ ۱ ﻣن ﻛل ۰۰۱ ﺷﺧص:(</p><p dir="RTL">&middot; &nbsp;&nbsp;&nbsp;اﻷﻧﻔﻠوﻧزا،</p><p dir="RTL">&middot; &nbsp;&nbsp;اﻛﺗﺋﺎب؛ ﻣﺷﻛﻠﺔ ﻓﻲ اﻟﻧوم إﺧﺗﻼل اﻟﻧوم،</p><p dir="RTL">&middot; &nbsp;&nbsp;&nbsp;اﻟدوﺧﺔ، ﺻداع؛ اﻻﺣﺳﺎس ﺑﺎﻟوﺧز،</p><p dir="RTL">&middot; &nbsp;&nbsp;&nbsp;ﺑطء ﺿرﺑﺎت اﻟﻘﻠب،</p><p dir="RTL">&middot; &nbsp;&nbsp;&nbsp;طﻔﺢ ﺟﻠدي،</p><p dir="RTL">&middot; &nbsp;&nbsp;&nbsp;ﺿﯾﻖ ﻓﻲ اﻟﺗﻧﻔس،</p><p dir="RTL">&middot; &nbsp;&nbsp;وﺟﻊ ﺑطن؛ اﻧﺗﻔﺎخ اﻟﺑطن إﻣﺳﺎك؛ ﻋﺳر اﻟﮭﺿم؛ اﻧﺗﻔﺎخ؛ ﺣرﻛﺎت اﻷﻣﻌﺎء اﻟﻣﺗﻛررة اﻟﺗﮭﺎب اﻟﻣﻌدة. ﻏﺛﯾﺎن؛ اﺿطراب ﻓﻲ اﻟﻣﻌدة</p><p dir="RTL">ﻣﻌده ﻣﺿطرﺑﮫ،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; ﺣب اﻟﺷ&nbsp;َﺑﺎب؛&nbsp;ﻗﺷﻌرﯾرة،</p><p dir="RTL">&middot; &nbsp;&nbsp;اﻟم اﻟﻣﻔﺎﺻل؛ أﻟم ﻓﻲ اﻟظﮭر؛ ﺗﺷﻧﺟﺎت اﻟﺳﺎق؛ اﻟﺗﻌب اﻟﻌﺿﻠﻲ أو اﻟﺗﺷﻧﺟﺎت أو اﻟﺿﻌف. أﻟم ﻓﻲ اﻟذراﻋﯾن واﻟﺳﺎﻗﯾن،</p><p dir="RTL">&middot; &nbsp;&nbsp;ﺿﻌف ﻏﯾر ﻋﺎدي. اﻟﺷﻌور ﺑﺎﻟﺗﻌب أو اﻟﺗوﻋك. ﺗورم، وﺧﺎﺻﺔ ﻓﻲ اﻟﻛﺎﺣﻠﯾن )وذﻣﺔ(،</p><p dir="RTL">&middot; &nbsp;&nbsp;اﻻرﺗﻔﺎﻋﺎت ﻓﻲ ﺑﻌض اﺧﺗﺑﺎرات اﻟدم اﻟﻣﻌﻣﻠﯾﺔ ﻟوظﯾﻔﺔ اﻟﻛﺑد أو اﻟﻌﺿﻼت(CK) ،</p><p dir="RTL">&middot; &nbsp;&nbsp;&nbsp;زﯾﺎدة اﻟوزن.</p><p dir="RTL">ﺑﺎﻹﺿﺎﻓﺔ إﻟﻰ ذﻟك، ﺗم اﻹﺑﻼغ ﻋن اﻵﺛﺎر اﻟﺟﺎﻧﺑﯾﺔ اﻟﺗﺎﻟﯾﺔ ﻋﻧد اﻷﺷﺧﺎص اﻟذﯾن ﺗﻧﺎوﻟوا إزﯾﺗﻣﺎﯾب أو أﻗراص أﺗورﻓﺎﺳﺗﺎﺗﯾن:</p><p dir="RTL">&middot; &nbsp;&nbsp;ردود اﻟﻔﻌل اﻟﺗﺣﺳﺳﯾﺔ ﺑﻣﺎ ﻓﻲ ذﻟك ﺗورم اﻟوﺟﮫ واﻟﺷﻔﺗﯾن واﻟﻠﺳﺎن و / أو اﻟﺣﻠﻖ اﻟﺗﻲ ﻗد ﺗﺳﺑب ﺻﻌوﺑﺔ ﻓﻲ اﻟﺗﻧﻔس أو اﻟﺑﻠﻊ )واﻟﺗﻲ</p><p dir="RTL">ﺗﺗطﻠب اﻟﻌﻼج ﻋﻠﻰ اﻟﻔور.(</p><p dir="RTL">&middot; &nbsp;&nbsp;ظﮭور طﻔﺢ ﺟﻠدي أﺣﻣر، ﻣﻊ ظﮭور آﻓﺎت ﻋﻠﻰ ﺷﻛل ﺑﺛور ﻓﻲ ﺑﻌض اﻷﺣﯾﺎن.</p><p dir="RTL">&middot; &nbsp;&nbsp;&nbsp;ﻣﺷﺎﻛل ﻓﻲ اﻟﻛﺑد،</p><p dir="RTL">&middot; &nbsp;&nbsp;&nbsp;ﺳﻌﺎل،</p><p dir="RTL">&middot; &nbsp;&nbsp;&nbsp;ﺣرﻗﺔ ﻓﻲ اﻟﻣﻌدة،</p><p dir="RTL">&middot; &nbsp;&nbsp;&nbsp;ﻗﻠﺔ اﻟﺷﮭﯾﺔ؛ ﻓﻘدان اﻟﺷﮭﯾﺔ،</p><p dir="RTL">&middot; &nbsp;&nbsp;&nbsp;ﺿﻐط دم ﻣرﺗﻔﻊ،</p><p dir="RTL">&middot; &nbsp;&nbsp;طﻔﺢ ﺟﻠدي وﺣﻛﺔ. ردود اﻟﻔﻌل اﻟﺗﺣﺳﺳﯾﺔ ﺑﻣﺎ ﻓﻲ ذﻟك اﻟطﻔﺢ اﻟﺟﻠدي وﺧﻼﯾﺎ اﻟﺷرى،</p><p dir="RTL">&middot; &nbsp;&nbsp;&nbsp;إﺻﺎﺑﺔ اﻟوﺗر،</p><p dir="RTL">&middot; &nbsp;&nbsp;ﺣﺻوات اﻟﻣرارة أو اﻟﺗﮭﺎب اﻟﻣرارة )اﻟذي ﻗد ﯾﺳﺑب آﻻم ﻓﻲ اﻟﺑطن، واﻟﻐﺛﯾﺎن، واﻟﻘﻲء.(</p><p dir="RTL">&middot; &nbsp;&nbsp;اﻟﺗﮭﺎب اﻟﺑﻧﻛرﯾﺎس ﻓﻲ ﻛﺛﯾر ﻣن اﻷﺣﯾﺎن ﻣﻊ آﻻم ﺷدﯾدة ﻓﻲ اﻟﺑطن.</p><p dir="RTL">&middot; &nbsp;&nbsp;اﻧﺧﻔﺎض ﻓﻲ ﻋدد ﺧﻼﯾﺎ اﻟدم، ﻣﻣﺎ ﻗد ﯾﺳﺑب ﻛدﻣﺎت / ﻧزﯾف )ﻗﻠﺔ اﻟﺻﻔﯾﺣﺎت.(</p><p dir="RTL">&middot; &nbsp;&nbsp;اﻟﺗﮭﺎب اﻟﺟﯾوب اﻷﻧﻔﯾﺔ. ﻧزﯾف اﻷﻧف،</p><p dir="RTL">&middot; &nbsp;&nbsp;&nbsp;أﻟم اﻟرﻗﺑﺔ؛ أﻟم؛ أﻟم ﺻدر؛ أﻟم ﻓﻲ اﻟﺣﻠﻖ</p><p dir="RTL">&middot; &nbsp;&nbsp;ارﺗﻔﺎع واﻧﺧﻔﺎض ﻣﺳﺗوﯾﺎت اﻟﺳﻛر ﻓﻲ اﻟدم )إذا ﻛﻧت ﻣﺻﺎ ًﺑﺎ ﺑداء اﻟﺳﻛري، ﯾﺟب أن ﺗﺳﺗﻣر ﻓﻲ اﻟﻣراﻗﺑﺔ اﻟدﻗﯾﻘﺔ ﻟﻣﺳﺗوﯾﺎت اﻟﺳﻛر</p><p dir="RTL">ﻓﻲ اﻟدم(،</p><p dir="RTL">&middot; &nbsp;&nbsp;&nbsp;وﺟود اﻟﻛواﺑﯾس،</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; ﺧدر أو وﺧز ﻓﻲ أﺻﺎﺑﻊ اﻟﯾدﯾن واﻟﻘدﻣﯾن،</p><p dir="RTL">&middot; &nbsp;&nbsp;&nbsp;إﻧﺧﻔﺎض اﻹﺣﺳﺎس ﺑﺎﻷﻟم أو اﻟﻠﻣس.</p><p dir="RTL">&middot; &nbsp;&nbsp;&nbsp;ﺗﻐﯾر ﻓﻲ ﺣﺎﺳﺔ اﻟﺗذوق. ﻓم ﺟﺎف،</p><p dir="RTL">&middot; &nbsp;&nbsp;&nbsp;ﻓﻘدان اﻟذاﻛرة،</p><p dir="RTL">&middot; &nbsp;&nbsp;رﻧﯾن ﻓﻲ اﻷذﻧﯾن و / أو اﻟرأس؛ ﻓﻘدان اﻟﺳﻣﻊ،</p><p dir="RTL">&middot; &nbsp;&nbsp;&nbsp;اﻟﻘﻲء،</p><p dir="RTL">&middot; &nbsp;&nbsp;&nbsp;اﻟﺗﺟﺷؤ،</p><p dir="RTL">&middot; &nbsp;&nbsp;&nbsp;ﺗﺳﺎﻗط اﻟﺷﻌر،</p><p dir="RTL">&middot; &nbsp;&nbsp;&nbsp;ارﺗﻔﺎع درﺟﺔ اﻟﺣرارة،</p><p dir="RTL">&middot; &nbsp;&nbsp;اﺧﺗﺑﺎرات اﻟﺑول اﻹﯾﺟﺎﺑﯾﺔ ﻟﺧﻼﯾﺎ اﻟدم اﻟﺑﯾﺿﺎء.</p><p dir="RTL">&middot; &nbsp;&nbsp;&nbsp;ﻋدم وﺿوح اﻟرؤﯾﺔ. اﺿطراﺑﺎت ﺑﺻرﯾﺔ،</p><p dir="RTL">&middot; &nbsp;&nbsp;اﻟﺗﺛدي )ﺗﺿﺧم اﻟﺛدي ﻋﻧد اﻟرﺟﺎل.(</p><p dir="RTL">اﻵﺛﺎر اﻟﺟﺎﻧﺑﯾﺔ اﻟﻣﺣﺗﻣﻠﺔ اﻟﻣﺑﻠﻎ ﻋﻧﮭﺎ ﻣﻊ ﺑﻌض اﻟﻌﻘﺎﻗﯾر اﻟﻣﺧﻔﺿﺔ ﻟﻠﻛوﻟﯾﺳﺗرول</p><p dir="RTL">&middot; &nbsp;&nbsp;&nbsp;اﻟﺻﻌوﺑﺎت اﻟﺟﻧﺳﯾﺔ،</p><p dir="RTL">&middot; &nbsp;&nbsp;&nbsp;اﻛﺗﺋﺎب،</p><p dir="RTL">&middot; &nbsp;&nbsp;ﻣﺷﺎﻛل ﻓﻲ اﻟﺗﻧﻔس ﺑﻣﺎ ﻓﻲ ذﻟك اﻟﺳﻌﺎل اﻟﻣﺳﺗﻣر و / أو ﺿﯾﻖ اﻟﺗﻧﻔس أو اﻟﺣﻣﻰ.</p><p dir="RTL">&middot; &nbsp;&nbsp;اﻟﺳﻛري. ﺗزداد اﺣﺗﻣﺎﻟﯾﺔ ﺣدوث ذﻟك إذا ﻛﺎن ﻟدﯾك ﻣﺳﺗوﯾﺎت ﻋﺎﻟﯾﺔ ﻣن اﻟﺳﻛرﯾﺎت واﻟدھون ﻓﻲ اﻟدم، وﺗﻌﺎﻧﻲ ﻣن زﯾﺎدة اﻟوزن</p><p dir="RTL">وارﺗﻔﺎع ﺿﻐط اﻟدم. ﺳﯾﻘوم طﺑﯾﺑك ﺑﻣراﻗﺑﺗك أﺛﻧﺎء ﺗﻧﺎوﻟك ﻟﮭذا اﻟدواء،</p><p dir="RTL">&middot; &nbsp;&nbsp;أﻟم ﻋﺿﻠﻲ أو رﻗﺔ أو ﺿﻌف ﻣﺳﺗﻣر وﺧﺎﺻﺔ إذا ﺷﻌرت، ﻓﻲ ﻧﻔس اﻟوﻗت، ﺑﺗوﻋك أو ارﺗﻔﺎع درﺟﺔ اﻟﺣرارة اﻟﺗﻲ ﻗد ﻻ ﺗزول</p><p dir="RTL">ﺑﻌد إﯾﻘﺎف أﺗوﻣﯾب )اﻟﺗردد ﻏﯾر ﻣﻌروف.(</p><p>اﻹﺑﻼغ ﻋن اﻵﺛﺎر اﻟﺟﺎﻧﺑﯾﺔ:</p><p dir="RTL">إن ﻛﺎن ﻟدﯾك أﻋراض ﺟﺎﻧﺑﯾﺔ أو ﻻﺣظت أﻋراض ﺟﺎﻧﺑﯾﺔ ﻏﯾر ﻣذﻛورة ﻓﻲ ھذه اﻟﻧﺷرة، ﻓﺿ&nbsp; ًﻼ اﺑﻠﻎ اﻟطﺑﯾب أو ﻣﻘدم اﻟرﻋﺎﯾﺔ اﻟﺻﺣﯾﺔ أو</p><p dir="RTL">اﻟﺻﯾدﻟﻲ.</p><p>&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>1.&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>كيفية تخزين </strong><strong>أتومیب أقراص</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احفظ هذا الدواء بعيدًا عن رؤية ومتناول أيدي الأطفال.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة بعد EXP. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من الشهر.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب تخزين هذا الدواء في درجة حرارة أقل من 30 درجة مئوية في العلبة الأصلية لحمايته من الرطوبة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتخلص من الأدوية في مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ومن شأن هذه التدابير أن تساعد على حماية البيئة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>آ</strong><strong>. ﻣﺎذا ﯾﺣﺗوي أﺗوﻣﯾب أﻗراص ﻋﻠﻰ</strong><strong>:</strong></p><p dir="RTL"><strong>أﺗوﻣﯾب ۰۱ ﻣﻠﺟرام </strong><strong>/ ۰۱ ﻣﻠﺟرام </strong><strong>)إزﯾﺗﻣﺎﯾب ۰۱ ﻣﻠﺟرام </strong><strong>/ أﺗورﻓﺎﺳﺗﺎﺗﯾن ۰۱ ﻣﻠﺟرام</strong><strong>(</strong></p><p dir="RTL">اﻟﺳواﻏﺎت اﻷﺧرى: اﻟﻼﻛﺗوز ﻣوﻧوھﯾدرات )اﻟﻛﻣﯾﺔ: ٥۱٫٦۲۱ ﻣﻠﺟرام( ﻛروﺳﻛﺎرﻣﯾﻠوز اﻟﺻودﯾوم )اﻟﻛﻣﯾﺔ: ۰۰٫٦۱ ﻣﻠﺟرام( إزﯾﺗﻣﺎﯾب</p><p dir="RTL">)اﻟﻛﻣﯾﺔ: ۰۰٫۰۱ ﻣﻠﺟرام( ﺑوﻟﻲ ﻓﯾﻧﯾل ﺑﯾروﻟﯾدون )اﻟﻛﻣﯾﺔ: ۰۰٫۹ ﻣﻠﺟرام( ﻛﺑرﯾﺗﺎت ﻟورﯾل اﻟﺻودﯾوم )اﻟﻛﻣﯾﺔ: ٥۸٫۳ ﻣل( ﻣﺎء ﻧﻘﻲ )ﻛﻣﯾﺔ ﻛﺎﻓﯾﺔ( اﻟﺳﻠﯾﻠوز دﻗﯾﻖ اﻟﺗﺑﻠور )اﻟﻛﻣﯾﺔ: ۰۰٫۲۳ ﻣﻠﺟرام( ﺳﺗﯾرات اﻟﻣﺎﻏﻧﯾﺳﯾوم )اﻟﻛﻣﯾﺔ: ۰۰٫۳ ﻣل( أﺗورﻓﺎﺳﺗﺎﺗﯾن ۰۱ ﻣﻠﺟرام</p><p dir="RTL">أﺗورﻓﺎﺳﺗﺎﺗﯾن ﻛﺎﻟﺳﯾوم ﺛﻼﺛﻲ ھﯾدرات ﻣﺎ ﯾﻌﺎدل أﺗورﻓﺎﺳﺗﺎﺗﯾن )اﻟﻛﻣﯾﺔ: ٥۲۸٫۰۱ ﻣﻠﺟرام ﻣن أﺗورﻓﺎﺳﺗﺎﺗﯾن ﻛﺎﻟﺳﯾوم ﺛﻼﺛﻲ ھﯾدرات ﻣﺎ ﯾﻌﺎدل</p><p dir="RTL">۰۰٫۰۱ ﻣﻠﺟرام ﻣن أﺗورﻓﺎﺳﺗﺎﺗﯾن(</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">اﻟﻼﻛﺗوز ﻣوﻧوھﯾدرات )اﻟﻛﻣﯾﺔ: ۰٦٫٦۲ ﻣﻠﺟرام( ﺳﻠﯾﻠوز دﻗﯾﻖ اﻟﺗﺑﻠور )اﻟﻛﻣﯾﺔ: ۰۰٫٤۲ ﻣﻠﺟرام( ﻛرﺑوﻧﺎت اﻟﻛﺎﻟﺳﯾوم )اﻟﻛﻣﯾﺔ: ۰۰٫۲۳</p><p dir="RTL">ﻣﻠﺟرام( ﻛروﺳﻛﺎرﻣﯾﻠوز اﻟﺻودﯾوم )اﻟﻛﻣﯾﺔ: ۰۰٫٦ ﻣﻠﺟرام(</p><p dir="RTL">ھﯾدروﻛﺳﻲ ﺑروﺑﯾل ﺳﻠﯾﻠوز )اﻟﻛﻣﯾﺔ: ۰۰٫۲ ﻣﻠﺟرام( ﺑوﻟﻲ ﺳورﺑﺎت ۰۸ )اﻟﻛﻣﯾﺔ: ۰٤٫۰ ﻣﻠﺟرام(</p><p dir="RTL">ﻣﺎء ﻧﻘﻲ )ﻛﻣﯾﺔ ﻛﺎﻓﯾﺔ(</p><p dir="RTL">اﻟﺳﯾﻠﯾﻛﺎ اﻟﻐروﯾﺔ اﻟﻼﻣﺎﺋﯾﺔ )اﻟﻛﻣﯾﺔ: ۰٥٫۰ ﻣﻠﺟرام( ﺳﺗﯾرات اﻟﻣﺎﻏﻧﯾﺳﯾوم )اﻟﻛﻣﯾﺔ: ۰۰٫۱ ﻣﻠﺟرام( @ أوﺑﺎدراي- II أﺑﯾض ۱۳G58920</p><p dir="RTL">)اﻟﻛﻣﯾﺔ: ۰٥٫٤ ﻣﻠﺟرام(</p><p>&nbsp;</p><p>&nbsp;</p><p>أﺗوﻣﯾب ۰۱ ﻣﻠﺟرام / ۰۲ ﻣﻠﺟرام )إزﯾﺗﻣﺎﯾب ۰۱ ﻣﻠﺟرام / أﺗورﻓﺎﺳﺗﺎﺗﯾن ۰۲ ﻣﻠﺟرام(</p><p dir="RTL">اﻟﺳواﻏﺎت اﻷﺧرى: اﻟﻼﻛﺗوز ﻣوﻧوھﯾدرات )اﻟﻛﻣﯾﺔ: ٥۱٫٦۲۱ ﻣﻠﺟرام( ﻛروﺳﻛﺎرﻣﯾﻠوز اﻟﺻودﯾوم )اﻟﻛﻣﯾﺔ: ۰۰٫٦۱ ﻣﻠﺟرام( إزﯾﺗﻣﺎﯾب</p><p dir="RTL">)اﻟﻛﻣﯾﺔ: ۰۰٫۰۱ ﻣﻠﺟرام( ﺑوﻟﻲ ﻓﯾﻧﯾل ﺑﯾروﻟﯾدون )اﻟﻛﻣﯾﺔ: ۰۰٫۹ ﻣﻠﺟرام( ﻛﺑرﯾﺗﺎت ﻟورﯾل اﻟﺻودﯾوم )اﻟﻛﻣﯾﺔ: ٥۸٫۳ ﻣل( ﻣﺎء ﻧﻘﻲ )ﻛﻣﯾﺔ ﻛﺎﻓﯾﺔ( اﻟﺳﻠﯾﻠوز دﻗﯾﻖ اﻟﺗﺑﻠور )اﻟﻛﻣﯾﺔ: ۰۰٫۲۳ ﻣﻠﺟرام( ﺳﺗﯾرات اﻟﻣﻐﻧﯾﺳﯾوم )اﻟﻛﻣﯾﺔ: ۰۰٫۳ ﻣل( أﺗورﻓﺎﺳﺗﺎﺗﯾن ۰۲ ﻣﻠﺟرام</p><p dir="RTL">أﺗورﻓﺎﺳﺗﺎﺗﯾن ﻛﺎﻟﺳﯾوم ﺛﻼﺛﻲ ھﯾدرات ﻣﺎ ﯾﻌﺎدل أﺗورﻓﺎﺳﺗﺎﺗﯾن )اﻟﻛﻣﯾﺔ: ٥٦٫۱۲ ﻣﻠﺟرام ﻣن أﺗورﻓﺎﺳﺗﺎﺗﯾن ﻛﺎﻟﺳﯾوم ﺛﻼﺛﻲ ھﯾدرات ﻣﺎ ﯾﻌﺎدل</p><p dir="RTL">۰۰٫۰۲ ﻣﻠﺟرام ﻣن أﺗورﻓﺎﺳﺗﺎﺗﯾن(</p><p dir="RTL">اﻟﻼﻛﺗوز ﻣوﻧوھﯾدرات )اﻟﻛﻣﯾﺔ: ۰۲٫۳٥ ﻣﻠﺟرام( ﺳﻠﯾﻠوز دﻗﯾﻖ اﻟﺗﺑﻠور )اﻟﻛﻣﯾﺔ: ۰۰٫۸٤ ﻣﻠﺟرام( ﻛرﺑوﻧﺎت اﻟﻛﺎﻟﺳﯾوم )اﻟﻛﻣﯾﺔ: ۰۰٫٤٦ ﻣﻠﺟرام( ﻛروﺳﻛﺎرﻣﯾﻠوز اﻟﺻودﯾوم )اﻟﻛﻣﯾﺔ: ۰۰٫۲۱ ﻣﻠﺟرام( ھﯾدروﻛﺳﻲ ﺑروﺑﯾل ﺳﻠﯾﻠوز )اﻟﻛﻣﯾﺔ: ۰۰٫٤ ﻣﻠﺟرام( ﺑوﻟﻲ ﺳورﺑﺎت ۰۸</p><p dir="RTL">)اﻟﻛﻣﯾﺔ: ۰۸٫۰ ﻣﻠﺟرام( ﻣﺎء ﻧﻘﻲ )ﻛﻣﯾﺔ ﻛﺎﻓﯾﺔ(</p><p dir="RTL">اﻟﺳﯾﻠﯾﻛﺎ اﻟﻐروﯾﺔ اﻟﻼﻣﺎﺋﯾﺔ )اﻟﻛﻣﯾﺔ: ۰۰٫۱ ﻣﻠﺟرام( ﺳﺗﯾرات اﻟﻣﺎﻏﻧﯾﺳﯾوم )اﻟﻛﻣﯾﺔ: ۰۰٫۲ ﻣل( @ أوﺑﺎدراي- II أﺑﯾض ۱۳G58920</p><p dir="RTL">)اﻟﻛﻣﯾﺔ: ۰۰٫٦ ﻣل(</p><p>&nbsp;</p><p>&nbsp;</p><p>أﺗوﻣﯾب ۰۱ ﻣﻠﺟرام / ۰٤ ﻣﻠﺟرام )إزﯾﺗﻣﺎﯾب ۰۱ ﻣﻠﺟرام / أﺗورﻓﺎﺳﺗﺎﺗﯾن ۰٤ ﻣﻠﺟرام(</p><p dir="RTL">اﻟﺳواﻏﺎت اﻷﺧرى: اﻟﻼﻛﺗوز ﻣوﻧوھﯾدرات )اﻟﻛﻣﯾﺔ: ٥۱٫٦۲۱ ﻣﻠﺟرام( ﻛروﺳﻛﺎرﻣﯾﻠوز اﻟﺻودﯾوم )اﻟﻛﻣﯾﺔ: ۰۰٫٦۱ ﻣﻠﺟرام( إزﯾﺗﻣﺎﯾب</p><p dir="RTL">)اﻟﻛﻣﯾﺔ: ۰۰٫۰۱ ﻣﻠﺟرام( ﺑوﻟﻲ ﻓﯾﻧﯾل ﺑﯾروﻟﯾدون )اﻟﻛﻣﯾﺔ: ۰۰٫۹ ﻣﻠﺟرام( ﻛﺑرﯾﺗﺎت ﻟورﯾل اﻟﺻودﯾوم )اﻟﻛﻣﯾﺔ: ٥۸٫۳ ﻣل( ﻣﺎء ﻧﻘﻲ )ﻛﻣﯾﺔ ﻛﺎﻓﯾﺔ( اﻟﺳﻠﯾﻠوز دﻗﯾﻖ اﻟﺗﺑﻠور )اﻟﻛﻣﯾﺔ: ۰۰٫۲۳ ﻣﻠﺟرام( ﺳﺗﯾرات اﻟﻣﺎﻏﻧﯾﺳﯾوم )اﻟﻛﻣﯾﺔ: ۰۰٫۳ ﻣل( أﺗورﻓﺎﺳﺗﺎﺗﯾن ۰٤ ﻣل</p><p dir="RTL">أﺗورﻓﺎﺳﺗﺎﺗﯾن ﻛﺎﻟﺳﯾوم ﺛﻼﺛﻲ ھﯾدرات ﻣﺎ ﯾﻌﺎدل أﺗورﻓﺎﺳﺗﺎﺗﯾن )اﻟﻛﻣﯾﺔ: ۰۳٫۳٤ ﻣﻠﺟرام ﻣن أﺗورﻓﺎﺳﺗﺎﺗﯾن ﻛﺎﻟﺳﯾوم ﺛﻼﺛﻲ ھﯾدرات ﻣﺎ ﯾﻌﺎدل</p><p dir="RTL">۰۰٫۰٤ ﻣﻠﺟرام ﻣن أﺗورﻓﺎﺳﺗﺎﺗﯾن(</p><p dir="RTL">اﻟﻼﻛﺗوز ﻣوﻧوھﯾدرات )اﻟﻛﻣﯾﺔ: ۰٤٫٦۰۱ ﻣﻠﺟرام( ﺳﻠﯾﻠوز دﻗﯾﻖ اﻟﺗﺑﻠور )اﻟﻛﻣﯾﺔ: ۰۰٫٦۹ ﻣﻠﺟرام( ﻛرﺑوﻧﺎت اﻟﻛﺎﻟﺳﯾوم )اﻟﻛﻣﯾﺔ: ۰۰٫۸۲۱</p><p dir="RTL">ﻣﻠﺟرام( ﻛروﺳﻛﺎرﻣﯾﻠوز اﻟﺻودﯾوم )اﻟﻛﻣﯾﺔ: ۰۰٫٤۲ ﻣﻠﺟرام(</p><p dir="RTL">ھﯾدروﻛﺳﻲ ﺑروﺑﯾل ﺳﻠﯾﻠوز )اﻟﻛﻣﯾﺔ: ۰۰٫۸ ﻣﻠﺟرام( ﺑوﻟﻲ ﺳورﺑﺎت ۰۸ )اﻟﻛﻣﯾﺔ: ۰٦٫۱ ﻣﻠﺟرام(</p><p dir="RTL">ﺗﻧﻘﯾﺔ اﻟﻣﯾﺎه )ﻛﻣﯾﺔ ﻛﺎﻓﯾﺔ(</p><p dir="RTL">اﻟﺳﯾﻠﯾﻛﺎ اﻟﻐروﯾﺔ اﻟﻼﻣﺎﺋﯾﺔ )اﻟﻛﻣﯾﺔ: ۰۰٫۲ ﻣﻠﺟرام( ﺳﺗﯾرات اﻟﻣﺎﻏﻧﯾﺳﯾوم )اﻟﻛﻣﯾﺔ: ۰۰٫٤ ﻣﻠﺟرام( @ أوﺑﺎدراي II -أﺑﯾض ۱۳ G58920</p><p dir="RTL">)اﻟﻛﻣﯾﺔ: ۰۰٫۹ ﻣﻠﺟرام(</p><p>&nbsp;</p><p>رﻗمE</p><p>E464</p><p>&nbsp;</p><p>ﯾﺗﻛون @ أوﺑﺎدراي 31G58920 White II -</p><p>(Ph. Eur. ،USP) ھﯾﺑروﻣﯾﻠﻠوز /HPMC 2910</p><p>&nbsp;</p><p dir="RTL">اﻟﻼﻛﺗوز ﻣوﻧوھﯾدرات&nbsp;&nbsp; USP)، Eur. (Ph.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>E171 E1521 E553b</p><p>&nbsp;</p><p dir="RTL">&nbsp;</p><p>E171 E1521 E553b</p><p>&nbsp;</p><p dir="RTL">ﺛﺎﻧﻲ أﻛﺳﯾد اﻟﺗﯾﺗﺎﻧﯾوم USP)، Eur. (Ph.</p><p>.(Ph. Eur. ،NF) / PEG MW 4000 ﻣﺎﻛروﺟول</p><p>(Ph. Eur. ،USP) اﻟﺗﻠك</p><p>&nbsp;</p><p>E1521</p><p>&nbsp;</p><p>(Ph. Eur. ،NF)PEG MW 400</p><p>&nbsp;</p><p dir="RTL">ﻣﺎﻛروﺟول /</p><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>أتومیب 10 ملجرام / 10 ملجرام </strong></p><p dir="RTL">أقراص على شكل كبسولة بيضاء إلى الأبيض المائل للصفرة، محدبة من الجانبين، مغلفة بطبقة رقيقة، مدموغ عليها &quot;1T&quot; على جانب واحد وملساء من الجانب الآخر.</p><p dir="RTL"><strong>أتومیب 10 ملجرام / 20 ملجرام</strong></p><p dir="RTL">أقراص على شكل كبسولة بيضاء إلى الأبيض المائل للصفرة، محدبة من الجانبين، مغلفة بطبقة رقيقة، مدموغ عليها &quot;2T&quot; على جانب واحد وملساء من الجانب الآخر.</p><p dir="RTL"><strong>أتومیب 10 ملجرام / 40 ملجرام</strong></p><p dir="RTL">أقراص على شكل كبسولة بيضاء إلى الأبيض المائل للصفرة، محدبة من الجانبين، مغلفة بطبقة رقيقة، مدموغ عليها &quot;4T&quot; على جانب واحد وملساء من الجانب الآخر.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ت.&nbsp;&nbsp;&nbsp; كيفية توفير أتومیب أقراص ومحتويات العبوة</strong>:</p><p dir="RTL">يتوافر أتومیب في شرائط تحتوي على 10 أقراص مصنوعة من Alu Alu ومغلفة بغلاف مطبوع ومصنوع من Alu Alu.</p><p dir="RTL">يتم توفير أتومیب في عبوة تحتوي على ثلاثة شرائط بكل منهما 10 أقراص والنشرة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>صاحب حق التسويق</strong><strong>:</strong></p><p><strong>شركة أماروكس السعودية للصناعة</strong></p><p>شارع الجامعة ، حي الملز</p><p>الرياض 12629 ، المملكة العربية السعودية</p><p>هاتف و فاكس: 966112268850+</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>المصنع</strong><strong>: </strong></p><p dir="RTL">إند سويفت المحدودة - الهند.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            
تمت مراجعة هذه النشرة في أكتوبر 2022 ، نسخة 1

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ATOMIBE 10mg/10mg (Ezetimibe 10mg and Atorvastatin 10mg Tablets) ATOMIBE 10mg/20mg (Ezetimibe 10mg and Atorvastatin 20mg Tablets) ATOMIBE 10mg/40mg (Ezetimibe 10mg and Atorvastatin 40mg Tablets)
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ATOMIBE 10mg/10mg (Ezetimibe 10mg and Atorvastatin 10mg Tablets)
Each film coated bilayered tablet contains:
Ezetimibe 10mg
Atorvastatin (as atorvastatin calcium trihydrate) Ph. Eur. 10 mg Colours: Titanium Dioxide
ATOMIBE 10mg/20mg (Ezetimibe 10mg and Atorvastatin 20mg Tablets)
Each film coated bilayered tablet contains:
Ezetimibe 10mg
Atorvastatin (as atorvastatin calcium trihydrate) Ph. Eur. 20 mg Colours: Titanium Dioxide
ATOMIBE 10mg/40mg (Ezetimibe 10mg and Atorvastatin 40mg Tablets)
Each film coated bilayered tablet contains:
Ezetimibe 10mg
Atorvastatin (as atorvastatin calcium trihydrate) Ph. Eur. 40 mg Colours: Titanium Dioxide
For a full list of Excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film Coated Tablet.
ATOMIBE 10mg/10mg (Ezetimibe 10mg and Atorvastatin 10mg Tablets)
White to off white, capsule shaped, biconvex, film coated tablets with one side debossed “1T” and other side plain.
ATOMIBE 10mg/20mg (Ezetimibe 10mg and Atorvastatin 20mg Tablets)
White to off white, capsule shaped, biconvex, film coated tablets with one side debossed “2T” and other side plain.
ATOMIBE 10mg/40mg (Ezetimibe 10mg and Atorvastatin 40mg Tablets)
White to off white, capsule shaped, biconvex, film coated tablets with one side debossed “4T” and other side plain.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Therapeutic Indications:<br />Prevention of Cardiovascular Events<br />ATOMIBE (Ezetimibe/Atorvastatin) is indicated to reduce the risk of cardiovascular events (see section 5.1) in patients with coronary heart disease (CHD) and a history of acute coronary syndrome (ACS), either previously treated with a statin or not.<br />Hypercholesterolaemia<br />ATOMIBE (Ezetimibe/Atorvastatin) is indicated as adjunctive therapy to diet for use in adults with primary (heterozygous familial and non-familial) hypercholesterolaemia or mixed hyperlipidaemia where use of a combination product is appropriate.<br />&bull; patients not appropriately controlled with a statin alone<br />&bull; patients already treated with a statin and ezetimibe<br />Homozygous Familial Hypercholesterolaemia (HoFH)<br />ATOMIBE (Ezetimibe/Atorvastatin) is indicated as adjunctive therapy to diet for use in adults with HoFH. Patients may also receive adjunctive treatments (e.g. low-density lipoprotein [LDL] apheresis).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology<br />Hypercholesterolaemia and/or Coronary Heart Disease (with ACS History)<br />The patient should be on an appropriate lipid-lowering diet and should continue on this diet during treatment with ATOMIBE.<br />The dose range of ATOMIBE is 10/10 mg/day through 80/10 mg/day. The typical dose is 10/10 mg once a day. The patient&rsquo;s low-density lipoprotein cholesterol (LDL-C) level, coronary heart disease risk status, and response to current cholesterol-lowering therapy should be considered when starting therapy or adjusting the dose.<br />The dose of ATOMIBE should be individualised based on the known efficacy of the various dose strengths of ATOMIBE (see section 5.1, Table 4) and the response to the current cholesterol- lowering therapy. Adjustment of dose should be made at intervals of 4 weeks or more.<br />3<br />Homozygous Familial Hypercholesterolaemia<br />The dose of ATOMIBE in patients with homozygous FH is 10/10 to 80/10 mg daily. ATOMIBE may be used as an adjunct to other lipid-lowering treatments (e.g. LDL apheresis) in these patients or if such treatments are unavailable.<br />Co-administration with other medicines<br />Dosing of ATOMIBE should occur either &ge;2 hours before or &ge;4 hours after administration of a<br />bile acid sequestrant.<br />In patients taking hepatitis C antiviral agents elbasvir/grazoprevir concomitantly with ATOMIBE, the dose of ATOMIBE should not exceed 20/10 mg/day (see sections 4.4 and 4.5).<br />Elderly<br />No dose adjustment is required for older patients (see section 5.2).<br />Paediatric population<br />The safety and efficacy of ATOMIBE in children has not been established (see section 5.2). No data are available.<br />Hepatic impairment<br />ATOMIBE should be used with caution in patients with hepatic impairment (see sections 4.4 and 5.2).<br />ATOMIBE is contraindicated in patients with active liver disease (see section 4.3).<br />Renal impairment<br />No dose adjustment is required for renally impaired patients (see section 5.2). Method of administration<br />ATOMIBE is for oral administration. ATOMIBE can be administered as a single dose at any time of the day, with or without food.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Therapy with ATOMIBE is contraindicated during pregnancy and breast-feeding, and in women of child-bearing potential not using appropriate contraceptive measures (see section 4.6).
ATOMIBE is contraindicated in patients with active liver disease or unexplained persistent elevations in serum transaminases exceeding 3 times the upper limit of normal (ULN).
ATOMIBE is contraindicated in patients treated with the hepatitis C antivirals glecaprevir/pibrentasvir.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Myopathy/Rhabdomyolysis<br />In post-marketing experience with ezetimibe, cases of myopathy and rhabdomyolysis have been reported. Most patients who developed rhabdomyolysis were taking a statin concomitantly with ezetimibe. However, rhabdomyolysis has been reported very rarely with ezetimibe monotherapy and very rarely with the addition of ezetimibe to other agents known to be associated with increased risk of rhabdomyolysis.<br />ATOMIBE contains atorvastatin. Atorvastatin, like other HMG-CoA reductase inhibitors, may in rare occasions affect the skeletal muscle and cause myalgia, myositis, and myopathy that may progress to rhabdomyolysis, a potentially life-threatening condition characterised by markedly elevated creatine phosphokinase (CPK) levels (&gt; 10 times ULN), myoglobinaemia and myoglobinuria, which may lead to renal failure.<br />Before the treatment<br />ATOMIBE should be prescribed with caution in patients with pre-disposing factors for rhabdomyolysis. A CPK level should be measured before starting treatment in the following situations:<br />&bull; renal impairment,<br />&bull; hypothyroidism,<br />&bull; personal or familial history of hereditary muscular disorders,<br />&bull; previous history of muscular toxicity with a statin or fibrate,<br />&bull; previous history of liver disease and/or where substantial quantities of alcohol are consumed,<br />&bull; in elderly (age &gt; 70 years), the necessity of such measurement should be considered, according to the presence of other predisposing factors for rhabdomyolysis,<br />&bull; situations where an increase in plasma levels may occur, such as interactions (see section 4.5) and special populations including genetic subpopulations (see section 5.2).<br />In such situations, the risk of treatment should be considered in relation to possible benefit, and clinical monitoring is recommended.<br />If CPK levels are significantly elevated (&gt; 5 times ULN) at baseline, treatment should not be started.<br />Creatine phosphokinase measurement<br />Creatine phosphokinase (CPK) should not be measured following strenuous exercise or in the presence of any plausible alternative cause of CPK increase as this makes value interpretation difficult. If CPK levels are significantly elevated at baseline (&gt; 5 times ULN), levels should be remeasured within 5 to 7 days later to confirm the results.<br />Whilst on treatment<br />&bull; Patients must be asked to promptly report muscle pain, cramps, or weakness especially if accompanied by malaise or fever or if muscle signs and symptoms persist after discontinuing ATOMIBE<br />5<br />&bull; If such symptoms occur whilst a patient is receiving treatment with ATOMIBE, their CPK levels should be measured. If these levels are found to be significantly elevated (&gt; 5 times ULN), treatment should be stopped.<br />&bull; If muscular symptoms are severe and cause daily discomfort, even if the CPK levels are<br />elevated to &le; 5 times ULN, treatment discontinuation should be considered.<br />&bull; If symptoms resolve and CPK levels return to normal, then re-introduction of ATOMIBE or introduction of another statin-containing product may be considered at the lowest dose and with close monitoring.<br />&bull; ATOMIBE must be discontinued if clinically significant elevation of CPK levels (&gt; 10 times ULN) occur, or if rhabdomyolysis is diagnosed or suspected.<br />&bull; There have been very rare reports of an immune-mediated necrotising myopathy (IMNM) during or after treatment with some statins. IMNM is clinically characterised by persistent proximal muscle weakness and elevated serum creatine kinase, which persist despite discontinuation of statin treatment.<br />Due to the atorvastatin component of ATOMIBE, the risk of rhabdomyolysis is increased when ATOMIBE is administered concomitantly with certain medicinal products that may increase the plasma concentration of atorvastatin such as potent inhibitors of CYP3A4 or transport proteins (e.g. ciclosporin, telithromycin, clarithromycin, delavirdine, stiripentol, ketoconazole, voriconazole, itraconazole, posaconazole, and HIV protease inhibitors including ritonavir, lopinavir, atazanavir, indinavir, darunavir, tipranavir/ritonavir, etc.). The risk of myopathy may also be increased with the concomitant use of gemfibrozil and other fibric acid derivatives, antivirals for the treatment of hepatitis C (HCV) (boceprevir, telaprevir, elbasvir/grazoprevir), erythromycin, or niacin. If possible, alternative (non-interacting) therapies should be considered instead of these medicinal products (see section 4.8).<br />In cases where co-administration of these medicinal products with ATOMIBE is necessary, the benefit and the risk of concurrent treatment should be carefully considered. When patients are receiving medicinal products that increase the plasma concentration of atorvastatin, a lower maximum dose of ATOMIBE is recommended. In addition, in the case of potent CYP3A4 inhibitors, a lower starting dose of ATOMIBE should be considered and appropriate clinical monitoring of these patients is recommended (see section 4.5).<br />Atorvastatin must not be co-administered with systemic formulations of fusidic acid or within 7 days of stopping fusidic acid treatment. In patients where the use of systemic fusidic acid is considered essential, statin treatment should be discontinued throughout the duration of fusidic acid treatment. There have been reports of rhabdomyolysis (including some fatalities) in patients receiving fusidic acid and statins in combination (see section 4.5). The patient should be advised to seek medical advice immediately if they experience any symptoms of muscle weakness, pain or tenderness.<br />Statin therapy may be re-introduced seven days after the last dose of fusidic acid.<br />In exceptional circumstances, where prolonged systemic fusidic acid is needed, e.g. for the treatment of severe infections, the need for co-administration of ATOMIBE and fusidic acid should only be considered on a case by case basis and under close medical supervision.<br />6<br />Daptomycin<br />Cases of myopathy and/or rhabdomyolysis have been reported with HMG-CoA reductase inhibitors (e.g. Ezetimibe and atorvastatin) co-administered with daptomycin. Caution should be used when prescribing HMG-CoA reductase inhibitors with daptomycin, as either agent can cause myopathy and/or rhabdomyolysis when given alone. Consideration should be given to temporarily suspend ATOMIBE in patients taking daptomycin unless the benefits of concomitant administration outweigh the risk. Consult the prescribing information of daptomycin to obtain further information about this potential interaction with HMG-CoA reductase inhibitors (e.g. Ezetimibe and Atorvastatin) and for further guidance related to monitoring (See section 4.5.).<br />Liver Enzymes<br />In controlled co-administration trials in patients receiving Ezetimibe/Atorvastation, consecutive transaminase elevations (&ge; 3 times the upper limit of normal [ULN]) have been observed (see section 4.8).<br />Liver function tests should be performed before the initiation of treatment and periodically thereafter. Patients who develop any signs or symptoms suggestive of liver injury should have liver function tests performed. Patients who develop increased transaminase levels should be monitored until the abnormality(ies) resolve. Should an increase in transaminases of greater than 3 times the ULN persist, reduction of dose or withdrawal of ATOMIBE is recommended.<br />ATOMIBE should be used with caution in patients who consume substantial quantities of alcohol and/or have a history of liver disease.<br />Hepatic Insufficiency<br />Due to the unknown effects of the increased exposure to ezetimibe in patients with moderate or severe hepatic insufficiency, ATOMIBE is not recommended (see section 5.2).<br />Fibrates<br />The safety and efficacy of ezetimibe administered with fibrates have not been established; therefore, co-administration of ATOMIBE and fibrates is not recommended (see section 4.5).<br />Ciclosporin<br />Caution should be exercised when initiating ATOMIBE in the setting of ciclosporin. Ciclosporin concentrations should be monitored in patients receiving ATOMIBE and ciclosporin (see section 4.5).<br />Anticoagulants<br />If ATOMIBE is added to warfarin, another coumarin anticoagulant, or fluindione, the International Normalised Ratio (INR) should be appropriately monitored (see section 4.5).<br />Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL)<br />In a post-hoc analysis of stroke subtypes in patients without coronary heart disease (CHD) who had a recent stroke or transient ischaemic attack (TIA) there was a higher incidence of haemorrhagic stroke in patients initiated on atorvastatin 80 mg compared to placebo.<br />7<br />The increased risk was particularly noted in patients with prior haemorrhagic stroke or lacunar infarct at study entry. For patients with prior haemorrhagic stroke or lacunar infarct, the balance of risks and benefits of atorvastatin 80 mg is uncertain, and the potential risk of haemorrhagic stroke should be carefully considered before initiating treatment (see section 5.1).<br />Interstitial lung disease<br />Exceptional cases of interstitial lung disease have been reported with some statins, especially with long-term therapy (see section 4.8). Presenting features can include dyspnoea, non- productive cough and deterioration in general health (fatigue, weight loss and fever). If it is suspected a patient has developed interstitial lung disease, statin therapy should be discontinued.<br />Diabetes mellitus<br />Some evidence suggests that statins as a class raise blood glucose and in some patients, at high risk of future diabetes, may produce a level of hyperglycaemia where formal diabetes care is appropriate. This risk, however, is outweighed by the reduction in vascular risk with statins and therefore should not be a reason for stopping statin treatment. Patients at risk (fasting glucose 5.6 to 6.9 mmol/L, BMI &gt; 30kg/m2, raised triglycerides, hypertension) should be monitored both clinically and biochemically according to national guidelines.<br />Excipients<br />ATOMIBE contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine.<br />ATOMIBE contains less than 1 mmol (23 mg) sodium per tablet and is considered to be essentially sodium-free.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Multiple mechanisms may contribute to potential interactions with HMG CoA reductase inhibitors. Drugs or herbal products that inhibit certain enzymes (e.g. CYP3A4) and/or transporter (e.g. OATP1B) pathways may increase atorvastatin plasma concentrations and may lead to an increased risk of myopathy/rhabdomyolysis.<br />Consult the prescribing information of all concomitantly used drugs to obtain further information about their potential interactions with atorvastatin and/or the potential for enzyme or transporter alterations and possible adjustments to dose and regimens.<br />Pharmacodynamic interactions<br />Atorvastatin is metabolised by cytochrome P450 3A4 (CYP3A4) and is a substrate of the hepatic transporters, organic anion-transporting polypeptide 1B1 (OATP1B1) and 1B3 (OATP1B3) transporter. Metabolites of atorvastatin are substrates of OATP1B1. Atorvastatin is also identified as a substrate of the multi-drug resistance protein 1 (MDR1) and breast cancer resistance protein (BCRP), which may limit the intestinal absorption and biliary clearance of atorvastatin (see section 5.2). Concomitant administration of medicinal products that are inhibitors of CYP3A4 or transport proteins may lead to increased plasma concentrations of atorvastatin and an increased risk of myopathy. The risk might also be increased at concomitant administration of Ezetimibe/Atorvastatin with other medicinal products that have a potential to induce myopathy, such as fibric acid derivatives and ezetimibe (see section 4.4).<br />8<br />Pharmacokinetic interactions<br />(Ezetimibe/Atorvastatin)<br />No clinically significant pharmacokinetic interaction was seen when atorvastatin was co- administered with Ezetimibe.<br />Effects of other medicinal products on (Ezetimibe/Atorvastatin)<br />Ezetimibe<br />Antacids: Concomitant antacid administration decreased the rate of absorption of ezetimibe but had no effect on the bioavailability of ezetimibe. This decreased rate of absorption is not considered clinically significant.<br />Cholestyramine: Concomitant cholestyramine administration decreased the mean area under the curve (AUC) of total ezetimibe (ezetimibe + ezetimibe-glucuronide) approximately 55%. The incremental low-density lipoprotein cholesterol (LDL-C) reduction due to adding Ezetimibe/Atorvastatin to cholestyramine may be lessened by this interaction (see section 4.2).<br />Ciclosporin: In a study of eight post-renal transplant patients with creatinine clearance of &gt; 50 mL/min on a stable dose of ciclosporin, a single 10-mg dose of ezetimibe resulted in a 3.4-fold (range 2.3 to 7.9 fold) increase in the mean AUC for total ezetimibe compared to a healthy control population, receiving ezetimibe alone, from another study (n = 17). In a different study, a renal transplant patient with severe renal insufficiency who was receiving ciclosporin and multiple other medicinal products demonstrated a 12-fold greater exposure to total ezetimibe compared to concurrent controls receiving ezetimibe alone. In a two-period crossover study in twelve healthy subjects, daily administration of 20 mg ezetimibe for 8 days with a single 100- mg dose of ciclosporin on Day 7 resulted in a mean 15% increase in ciclosporin AUC (range 10% decrease to 51% increase) compared to a single 100-mg dose of ciclosporin alone. A controlled study on the effect of co-administered ezetimibe on ciclosporin exposure in renal transplant patients has not been conducted. Caution should be exercised when initiating Ezetimibe/Atorvastatin in the setting of ciclosporin. Ciclosporin concentrations should be monitored in patients receiving Ezetimibe/Atorvastatin and ciclosporin (see section 4.4).<br />Fibrates: Concomitant fenofibrate or gemfibrozil administration increased total ezetimibe concentrations approximately 1.5 and 1.7 fold, respectively. Although these increases are not considered clinically significant, co-administration of Ezetimibe/Atorvastatin with fibrates is not recommended (see section 4.4).<br />Atorvastatin<br />CYP3A4 inhibitors: Potent CYP3A4 inhibitors have been shown to lead to markedly increased concentrations of atorvastatin (see Table 1 and specific information below). Co-administration of potent CYP3A4 inhibitors (e.g. ciclosporin, telithromycin, clarithromycin, delavirdine, stiripentol, ketoconazole, voriconazole, itraconazole, posaconazole, some antivirals used in the treatment of HCV (e.g. elbasvir/grazoprevir) and HIV protease inhibitors including ritonavir, lopinavir, atazanavir, indinavir, darunavir, etc.) should be avoided if possible. In cases where co-administration of these medicinal products with Ezetimibe/Atorvastatin cannot be avoided,<br />9<br />lower starting and maximum doses of Ezetimibe/Atorvastatin should be considered and appropriate clinical monitoring of the patient is recommended (see Table 1).<br />Moderate CYP3A4 inhibitors (e.g. erythromycin, diltiazem, verapamil and fluconazole) may increase plasma concentrations of atorvastatin (see Table 1). An increased risk of myopathy has been observed with the use of erythromycin in combination with statins. Interaction studies evaluating the effects of amiodarone or verapamil on atorvastatin have not been conducted. Both amiodarone and verapamil are known to inhibit CYP3A4 activity and co-administration with Ezetimibe/Atorvastatin may result in increased exposure to atorvastatin. Therefore, a lower maximum dose of Ezetimibe/Atorvastatin should be considered and appropriate clinical monitoring of the patient is recommended when concomitantly used with moderate CYP3A4 inhibitors. Appropriate clinical monitoring is recommended after initiation or following dose adjustments of the inhibitor.<br />Inhibitors of Breast Cancer Resistant Protein (BCRP): Concomitant administration of products that are inhibitors of BCRP (e.g. elbasvir and grazoprevir) may lead to increased plasma concentrations of atorvastatin and an increased risk of myopathy; therefore, a dose adjustment of atorvastatin should be considered depending on the prescribed dose. Co-administration of elbasvir and grazoprevir with atorvastatin increases plasma concentrations of atorvastatin 1.9- fold (see Table 1); therefore, the dose of Ezetimibe/Atorvastatin should not exceed 10/20 mg daily in patients receiving concomitant medications with products containing elbasvir or grazoprevir (see sections 4.2 and 4.4).<br />Inducers of cytochrome P450 3A4: Concomitant administration of atorvastatin with inducers of cytochrome P450 3A4 (e.g. efavirenz, rifampicin, St. John&#39;s wort) can lead to variable reductions in plasma concentrations of atorvastatin. Due to the dual interaction mechanism of rifampicin, (cytochrome P450 3A4 induction and inhibition of hepatocyte uptake transporter OATP1B1), simultaneous co-administration of Ezetimibe/Atorvastatin with rifampicin is recommended, as delayed administration of atorvastatin after administration of rifampicin has been associated with a significant reduction in atorvastatin plasma concentrations. The effect of rifampicin on atorvastatin concentrations in hepatocytes is, however, unknown and if concomitant administration cannot be avoided, patients should be carefully monitored for efficacy.<br />Transport inhibitors: Inhibitors of transport proteins (e.g. ciclosporin) can increase the systemic exposure of atorvastatin (see Table 1). The effect of inhibition of hepatic uptake transporters on atorvastatin concentrations in hepatocytes is unknown. If concomitant administration cannot be avoided, a dose reduction of Ezetimibe/Atorvastatin and clinical monitoring for efficacy is recommended (see Table 1).<br />Gemfibrozil / fibric acid derivatives: The use of fibrates alone is occasionally associated with muscle-related events, including rhabdomyolysis. The risk of these events may be increased with the concomitant use of fibric acid derivatives and atorvastatin.<br />Ezetimibe: The use of ezetimibe alone is associated with muscle-related events, including rhabdomyolysis. The risk of these events may therefore be increased with concomitant use of ezetimibe and atorvastatin. Appropriate clinical monitoring of these patients is recommended.<br />10<br />Colestipol: Plasma concentrations of atorvastatin and its active metabolites were lower (by approx. 25%) when colestipol was co-administered with atorvastatin. However, lipid effects were greater when atorvastatin and colestipol were co-administered than when either medicinal product was given alone.<br />Fusidic acid: The risk of myopathy including rhabdomyolysis may be increased by the concomitant administration of systemic fusidic acid with statins. The mechanism of this interaction (whether it is pharmacodynamic or pharmacokinetic, or both) is yet unknown. There have been reports of rhabdomyolysis (including some fatalities) in patients receiving this combination.<br />If treatment with systemic fusidic acid is necessary, atorvastatin treatment should be discontinued throughout the duration of the fusidic acid treatment. Also see section 4.4.<br />Colchicine: Although interaction studies with atorvastatin and colchicine have not been conducted, cases of myopathy have been reported with atorvastatin co-administered with colchicine, and caution should be exercised when prescribing atorvastatin with colchicine.<br />Daptomycin: The risk of myopathy and/or rhabdomyolysis may be increased by concomitant administration of HMG-CoA reductase inhibitors and daptomycin. Consideration should be given to suspending Ezetimibe/Atorvastatin temporarily in patients taking daptomycin unless the benefits of concomitant administration outweigh the risk (see section 4.4).<br />Boceprevir: Exposure to atorvastatin was increased when administered with boceprevir. When co-administration with Ezetimibe/Atorvastatin is required, starting with the lowest possible dose of Ezetimibe/Atorvastatin should be considered with titration up to desired clinical effect while monitoring for safety, without exceeding a daily dose of 10/20 mg. For patients currently taking Ezetimibe/Atorvastatin, the dose of Ezetimibe/Atorvastatin should not exceed a daily dose of 10/20 mg during co-administration with boceprevir.<br />Effects of Ezetimibe/Atorvastatin on the pharmacokinetics of other medicinal products Ezetimibe<br />In preclinical studies, it has been shown that ezetimibe does not induce cytochrome P450 drug metabolising enzymes. No clinically significant pharmacokinetic interactions have been observed between ezetimibe and drugs known to be metabolised by cytochromes P450 1A2, 2D6, 2C8, 2C9, and 3A4, or N-acetyltransferase.<br />Anticoagulants: Concomitant administration of ezetimibe (10 mg once daily) had no significant effect on bioavailability of warfarin and prothrombin time in a study of twelve healthy adult males. However, there have been post-marketing reports of increased International Normalised Ratio (INR) in patients who had ezetimibe added to warfarin or fluindione. If Ezetimibe/Atorvastatin is added to warfarin, another coumarin anticoagulant, or fluindione, INR should be appropriately monitored (see section 4.4).<br />11<br />Atorvastatin<br />Digoxin: When multiple doses of digoxin and 10 mg atorvastatin were co-administered, steady- state digoxin concentrations increased slightly. Patients taking digoxin should be monitored appropriately.<br />Oral contraceptives: Co-administration of atorvastatin with an oral contraceptive produced increases in plasma concentrations of norethisterone and ethinyl estradiol.<br />Warfarin: In a clinical study in patients receiving chronic warfarin therapy, co-administration of atorvastatin 80 mg daily with warfarin caused a small decrease of about 1.7 seconds in prothrombin time during the first 4 days of dosing, which returned to normal within 15 days of atorvastatin treatment. Although only very rare cases of clinically significant anticoagulant interactions have been reported, prothrombin time should be determined before starting Ezetimibe/Atorvastatin in patients taking coumarin anticoagulants and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs. Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants. If the dose of Ezetimibe/Atorvastatin is changed or discontinued, the same procedure should be repeated. Atorvastatin therapy has not been associated with bleeding or with changes in prothrombin time in patients not taking anticoagulants.<br />Table 1<br />Effect of Co-administered Medicinal Products on the Pharmacokinetics of Atorvastatin<br />Co-administered Medicinal Product and Dosing Regimen<br />Atorvastatin<br />Ezetimibe/Atorvastatin<br />Dose (mg)<br />Change in AUC&amp;<br />Clinical Recommendation#<br />Tipranavir 500 mg BID/ Ritonavir 200<br />mg BID, 8 days (Days 14 to 21)<br />40 mg on Day 1,<br />10 mg on Day 20<br />&uarr; 9.4-fold<br />In cases where co- administration with Ezetimibe/Atorvastatin is necessary, do not exceed 10/10 mg daily. Clinical monitoring of these<br />patients is recommended.<br />Ciclosporin 5.2 mg/kg/day, stable dose<br />10 mg OD for 28 days<br />&uarr; 8.7-fold<br />Lopinavir 400 mg BID/ Ritonavir 100 mg BID, 14 days<br />20 mg OD for 4 days<br />&uarr; 5.9-fold<br />In cases where co-administration with Ezetimibe/ Atorvastatin is necessary, lower maintenance dose Ezetimibe/ Atorvastatin are recommended Atorvastatin/ Ezetimibe doses exceeding 10/20<br />mg, clinical monitoring of these patients is recommended.<br />Clarithromycin 500 mg BID, 9 days<br />80 mg OD for 8 days<br />&uarr; 4.4-fold<br />Saquinavir 400 mg BID/ Ritonavir 300 mg BID from Days 5-7, increased to 400 mg BID on Day 8), Days 5-18, 30 min after atorvastatin dosing<br />40 mg OD for 4 days<br />&uarr; 3.9-fold<br />In cases where co- administration with Ezetimibe/Atorvastatin is necessary, lower maintenance doses of Ezetimibe/Atorvastatin are recommended. At Ezetimibe/Atorvastatin doses exceeding 10/40 mg, clinical monitoring of these patients is recommended.<br />Darunavir 300 mg BID/ Ritonavir 100 mg BID, 9 days<br />10 mg OD for 4 days<br />&uarr; 3.3-fold<br />Itraconazole 200 mg OD, 4 days<br />40 mg SD<br />&uarr; 3.3-fold<br />Fosamprenavir 700 mg BID/ Ritonavir 100 mg BID, 14 days<br />10 mg OD for 4 days<br />&uarr; 2.5-fold<br />Fosamprenavir 1,400 mg BID, 14 days<br />10 mg OD for 4 days<br />&uarr; 2.3-fold<br />12<br />Nelfinavir 1250 mg BID, 14 days<br />10 mg OD for 28 days<br />&uarr; 1.7-fold^<br />No specific recommendation.<br />Grapefruit juice, 240 mL OD*<br />40 mg SD<br />&uarr; 37%<br />Concomitant intake of large quantities of grapefruit juice and<br />Ezetimibe/Atorvastatin is not recommended.<br />Diltiazem 240 mg OD, 28 days<br />40 mg SD<br />&uarr; 51%<br />After initiation or following dose adjustments of diltiazem,<br />appropriate clinical monitoring of these patients is recommended.<br />Erythromycin 500 mg QID, 7 days<br />10 mg SD<br />&uarr; 33%^<br />Lower maximum dose and clinical monitoring of these patients is recommended.<br />Amlodipine 10 mg, single dose<br />80 mg SD<br />&uarr; 18%<br />No specific recommendation.<br />Cimetidine 300 mg QID, 2 weeks<br />10 mg OD for 4 weeks<br />&darr; less than 1%^<br />No specific recommendation.<br />Antacid suspension of magnesium<br />and aluminium hydroxides, 30 mL QID, 2 weeks<br />10 mg OD for 4 weeks<br />&darr; 35%^<br />No specific recommendation.<br />Efavirenz 600 mg OD, 14 days<br />10 mg for 3 days<br />&darr; 41%<br />No specific recommendation.<br />Rifampicin 600 mg OD, 7 days (co- administered)<br />40 mg SD<br />&uarr; 30%<br />If co-administration cannot be avoided, simultaneous co- administration of Ezetimibe/ Atorvastatin with rifampicin is<br />recommended, with clinical monitoring.<br />Rifampicin 600 mg OD, 5 days (doses separated)<br />40 mg SD<br />&darr; 80%<br />Gemfibrozil 600 mg BID, 7 days<br />40 mg SD<br />&uarr; 35%<br />Not recommended.<br />Fenofibrate 160 mg OD, 7 days<br />40 mg SD<br />&uarr; 3%<br />Not recommended.<br />Boceprevir 800 mg TID, 7 days<br />40 mg SD<br />&uarr; 2.3-fold<br />Lower starting dose and clinical monitoring of these patients is recommended. The dose of Ezetimibe/Atorvastatin should not exceed a daily dose of 10/20 mg<br />during co-administration with boceprevir.<br />Elbasvir 50 mg OD/Grazoprevir 200 mg OD, 13 days<br />10 mg SD<br />&uarr;1.94-fold<br />The dose of Ezetimibe/ Atorvastatin should not exceed a daily dose of 10/20 mg during co-<br />administration with products containing elbasvir or grazoprevir.<br />Glecaprevir 400 mg OD/Pibrentasvir 120 mg OD, 7 days<br />10 mg OD for 7 days<br />&uarr; 8.3-fold<br />Co-administration with products containing glecaprevir or pibrentasvir is contraindicated (see section 4.3).<br />&amp; Data given as x-fold change represent a simple ratio between co-administration and atorvastatin alone (i.e., 1- fold = no change). Data given as % change represent % difference relative to atorvastatin alone (i.e., 0% = no change)<br /># See sections 4.4 and 4.5 for clinical significance<br />* Contains one or more components that inhibit CYP3A4 and can increase plasma concentrations of medicinal products metabolised by CYP3A4. Intake of one 240 mL glass of grapefruit juice also resulted in a decreased AUC of 20.4% for the active orthohydroxy metabolite. Large quantities of grapefruit juice (over 1.2 l daily for 5 days) increased AUC of atorvastatin 2.5-fold and AUC of active (atorvastatin and metabolites)<br />^ Total atorvastatin equivalent activity<br />Increase is indicated as &ldquo;&uarr;&rdquo;, decrease as &ldquo;&darr;&rdquo;<br />OD = once daily; SD = single dose; BID = twice daily; TID = three times daily; QID = four times daily<br />13<br />Table 2<br />Effect of Atorvastatin on the Pharmacokinetics of Co-administered Medicinal Products<br />Atorvastatin and Dosing Regimen<br />Co-administered Medicinal Product<br />Ezetimibe/Atorvastatin<br />Medicinal Product/Dose (mg)<br />Change in AUC&amp;<br />Clinical Recommendation<br />80 mg OD for 10 days<br />Digoxin 0.25 mg OD, 20 days<br />&uarr; 15%<br />Patients taking digoxin should be monitored<br />Appropriately.<br />40 mg OD for 22 days<br />Oral contraceptive OD, 2 months<br />-norethisterone 1 mg<br />-ethinyl estradiol 35 micrograms<br />&uarr; 28%<br />&uarr; 19%<br />No specific recommendation.<br />80 mg OD for 15 days<br />* Phenazone, 600 mg SD<br />&uarr; 3%<br />No specific recommendation<br />10 mg OD for 4 days<br />Fosamprenavir 1,400 mg BID, 14 days<br />&darr; 27%<br />No specific recommendation<br />&amp; Data given as % change represent % difference relative to atorvastatin alone (i.e., 0% = no change)<br />* Co-administration of multiple doses of atorvastatin and phenazone showed little or no detectable effect in the clearance of phenazone<br />Increase is indicated as &ldquo;&uarr;&rdquo;, decrease as &ldquo;&darr;&rdquo;<br />OD = once daily; SD = single dose; BID = twice daily</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Women of childbearing potential<br />Women of childbearing potential should use appropriate contraceptive measures during treatment (see section 4.3).<br />Pregnancy<br />Atherosclerosis is a chronic process, and ordinarily discontinuation of lipid-lowering drugs during pregnancy should have little impact on the long-term risk associated with primary hypercholesterolaemia.<br />Ezetimibe/Atorvastatin is contraindicated during pregnancy (see section 4.3). No clinical data are available on the use of Ezetimibe/Atorvastatin during pregnancy. Ezetimibe/Atorvastatin should not be used in women who are pregnant, trying to become pregnant or suspect they are pregnant. Treatment with Ezetimibe/Atorvastatin should be suspended for the duration of pregnancy or until it has been determined that the woman is not pregnant (see section 4.3).<br />The co-administration of Ezetimibe/Atorvastatin in pregnant rats indicated that there was a test article-related increase in the skeletal variation &ldquo;reduced ossification of the sternebrae&rdquo; in the high dose ezetimibe/atorvastatin group. This may be related to the observed decrease in foetal body weights. In pregnant rabbits a low incidence of skeletal deformities (fused sternebrae, fused caudal vertebrae and asymmetrical sternebrae variation) were observed.<br />Atorvastatin<br />Safety in pregnant women has not been established. No controlled clinical trials with atorvastatin have been conducted in pregnant women. Rare reports of congenital anomalies following intrauterine exposure to HMG-CoA reductase inhibitors have been received. Animal studies have shown toxicity to reproduction (see section 5.3). Maternal treatment with atorvastatin may reduce the foetal levels of mevalonate which is a precursor of cholesterol biosynthesis.<br />14<br />Ezetimibe<br />No clinical data are available on the use of ezetimibe during pregnancy. Animal studies on the use of ezetimibe in monotherapy have shown no evidence of direct or indirect harmful effects on pregnancy, embryofoetal development, birth or postnatal development (see section 5.3).<br />Breast-feeding<br />Ezetimibe/Atorvastatin is contraindicated during breast-feeding. Because of the potential for serious adverse reactions, women taking Ezetimibe/Atorvastatin should not breast-feed their infants. Studies on rats have shown that ezetimibe is secreted into breast milk. In rats, plasma concentrations of atorvastatin and its active metabolites are similar to those in milk. It is not known if the active components of Ezetimibe/Atorvastatin are secreted into human breast milk (see section 4.3).<br />Fertility<br />No fertility studies were conducted with Ezetimibe/Atorvastatin.<br />Atorvastatin<br />In animal studies atorvastatin had no effect on male or female<br />Ezetimibe<br />Ezetimibe had no effect on the fertility of male or female rats.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ezetimibe/Atorvastatin has negligible influence on the ability to drive and use machines. However, when driving vehicles or operating machines, it should be taken into account that dizziness has been reported.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of the safety profile<br />The co-administration of atorvastatin and ezetimibe has been evaluated for safety in more than 2,400 patients in 7 clinical trials.<br />Tabulated list of adverse reactions<br />Adverse reactions observed in clinical studies of co-administration of Ezetimibe/Atorvastatin orreported from post-marketing use with Ezetimibe/Atorvastatin are listed in Table 3. These reactions are presented by system organ class and by frequency. Frequencies are defined as: very common (&ge;1/10); common &ge;1/100, &lt;1/10); uncommon (&ge;1/1000, &lt;1/100); rare (&ge;1/10,000,<br />&lt;1/1000); very rare (&lt;1/10,000); and not known (cannot be estimated from the available data).<br />15<br />Table 3 Adverse Reaction<br />System organ class<br />Frequency<br />Adverse reaction<br />Infections and infestations<br />Uncommon<br />influenza<br />Not known<br />nasopharyngitis<br />Blood and lymphatic system disorders<br />Not known<br />thrombocytopenia<br />Immune system disorders<br />Not known<br />hypersensitivity, including anaphylaxis, angioedema, rash, and urticaria<br />Metabolism and nutrition disorders<br />Not known<br />decreased appetite; anorexia; hyperglycaemia; hypoglycaemia<br />Psychiatric disorders<br />Uncommon<br />depression; insomnia; sleep disorder<br />Not known<br />nightmares<br />Nervous system disorders<br />Uncommon<br />dizziness; dysgeusia; headache; paraesthesia<br />Not known<br />hypoesthesia; amnesia; peripheral neuropathy<br />Eye disorders<br />Not known<br />vision blurred; visual disturbance<br />Ear and labyrinth disorders<br />System organ class<br />Frequency<br />Adverse reaction<br />Not known<br />tinnitus; hearing loss<br />Cardiac disorders<br />Uncommon<br />sinus bradycardia<br />Vascular disorders<br />Uncommon<br />hot flush<br />Not known<br />hypertension<br />Respiratory, thoracic and mediastinal disorders<br />Uncommon<br />dyspnoea<br />Not known<br />cough; pharyngolaryngeal pain; epistaxis<br />Gastrointestinal disorders<br />Common<br />diarrhoea<br />Uncommon<br />abdominal discomfort; abdominal distension; abdominal pain; abdominal pain lower; abdominal pain upper; constipation; dyspepsia; flatulence; frequent bowel movements; gastritis; nausea; stomach discomfort<br />Not known<br />pancreatitis; gastro-oesophageal reflux disease; eructation; vomiting; dry mouth<br />Hepatobiliary disorders<br />Not known<br />hepatitis; cholelithiasis; cholecystitis; cholestasis; fatal and non-fatal hepatic failure<br />Skin and subcutaneous tissue disorders<br />Uncommon<br />acne; urticaria<br />16<br />Not known<br />alopecia; skin rash; pruritus; erythema multiforme; angioneurotic oedema; dermatitis bullous including<br />erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis<br />Musculoskeletal and connective tissue disorders<br />Common<br />myalgia<br />Uncommon<br />arthralgia; back pain; muscle fatigue; muscle spasms; muscular weakness; pain in extremity<br />Not known<br />myopathy/rhabdomyolysis; muscle rupture; tendinopathy, sometimes complicated by rupture; neck pain; joint swelling; myositis; lupus-like<br />syndrome; immune-mediated necrotizing myopathy (see section 4.4)<br />Reproductive system and breast disorders<br />Not known<br />gynaecomastia<br />General disorders and administration site conditions<br />Uncommon<br />asthenia; fatigue; malaise; oedema<br />System organ class Frequency<br />Adverse reaction<br />Not known<br />chest pain; pain; peripheral oedema; pyrexia<br />Investigations<br />Uncommon<br />ALT and/or AST increased; alkaline phosphatase increased; blood creatine phosphokinase (CPK) increased; gamma-glutamyltransferase increased;<br />hepatic enzyme increased; liver function test abnormal; weight increased<br />Not known<br />white blood cells urine positive<br />Laboratory Values<br />In controlled clinical trials, the incidence of clinically important elevations in serum transaminases (ALT and/or AST &ge;3 X ULN, consecutive) was 0.6% for patients treated with Ezetimibe/Atorvastatin. These elevations were generally asymptomatic, not associated with cholestasis, and returned to baseline spontaneously or after discontinuation of therapy (see section 4.4).<br />The following adverse events have been reported with some statins:<br />&bull; sexual dysfunction<br />&bull; exceptional cases of interstitial lung disease, especially with long-term therapy (see section 4.4)<br />&bull; diabetes mellitus: frequency will depend on the presence or absence of risk factors (fasting<br />blood glucose &ge; 5.6 mmol/L, BMI&gt; 30 kg/m2, raised triglycerides, history of hypertension)<br />Reporting of suspected adverse reactions<br />If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.<br />To report any side effect(s):<br />Saudi Arabia:<br />17<br />&bull; The National Pharmacovigilance Centre (NPC):<br />- SFDA Call Center: 19999<br />- E-mail: npc.drug@sfda.gov.sa<br />- Website: https://ade.sfda.gov.sa/<br />- Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ezetimibe/Atorvastatin<br />In the event of an overdose, symptomatic and supportive measures should be employed. Liver function tests should be performed and serum CPK levels should be monitored.<br />Ezetimibe<br />In clinical studies, administration of ezetimibe, 50 mg/day to 15 healthy subjects for up to 14 days, or 40 mg/day to 18 patients with primary hyperlipidaemia for up to 56 days, was generally well tolerated. A few cases of overdose have been reported; most have not been associated with adverse experiences. Reported adverse experiences have not been serious. In animals, no toxicity was observed after single oral doses of 5,000 mg/kg of ezetimibe in rats and mice and 3,000 mg/kg in dogs.<br />Atorvastatin<br />Due to extensive atorvastatin binding to plasma proteins, haemodialysis is not expected to significantly enhance atorvastatin clearance.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Lipid modifying agents, HMG-CoA reductase inhibitors in combination with other lipid modifying agents, ATC code: C10BA05<br />Ezetimibe/Atorvastatin is a lipid-lowering product that selectively inhibits the intestinal absorption of cholesterol and related plant sterols and inhibits the endogenous synthesis of cholesterol.<br />Mechanism of action Ezetimibe/Atorvastatin<br />Plasma cholesterol is derived from intestinal absorption and endogenous synthesis. Ezetimibe/Atorvastatin, two lipid-lowering compounds with complementary mechanisms of action. Ezetimibe/Atorvastatin reduces elevated total cholesterol (total-C), LDL-C, apolipoprotein B (Apo B), triglycerides (TG), and non-high-density lipoprotein cholesterol (non-<br />18<br />HDL-C), and increases high-density lipoprotein cholesterol (HDL-C) through dual inhibition of cholesterol absorption and synthesis.<br />Ezetimibe<br />Ezetimibe inhibits the intestinal absorption of cholesterol. Ezetimibe is orally active and has a mechanism of action that differs from other classes of cholesterol-reducing compounds (e.g. statins, bile acid sequestrants [resins], fibric acid derivatives, and plant stanols). The molecular target of ezetimibe is the sterol transporter, Niemann-Pick C1-Like 1 (NPC1L1), which is responsible for the intestinal uptake of cholesterol and phytosterols.<br />Ezetimibe localises at the brush border of the small intestine and inhibits the absorption of cholesterol, leading to a decrease in the delivery of intestinal cholesterol to the liver; statins reduce cholesterol synthesis in the liver and together these distinct mechanisms provide complementary cholesterol reduction. In a 2-week clinical study in 18 hypercholesterolaemic patients, ezetimibe inhibited intestinal cholesterol absorption by 54%, compared with placebo.<br />A series of preclinical studies was performed to determine the selectivity of ezetimibe for inhibiting cholesterol absorption. Ezetimibe inhibited the absorption of [14C]-cholesterol with no effect on the absorption of triglycerides, fatty acids, bile acids, progesterone, ethinyl estradiol, or fat soluble vitamins A and D.<br />Atorvastatin<br />Atorvastatin is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme responsible for the conversion of 3-hydroxy-3-methyl-glutaryl-coenzyme A to mevalonate, a precursor of sterols, including cholesterol. Triglycerides and cholesterol in the liver are incorporated into very low-density lipoproteins (VLDL) and released into the plasma for delivery to peripheral tissues. Low-density lipoprotein (LDL) is formed from VLDL and is catabolised primarily through the receptor with high affinity to LDL (LDL receptor).<br />Atorvastatin lowers plasma cholesterol and lipoprotein serum concentrations by inhibiting HMG- CoA reductase and subsequently cholesterol biosynthesis in the liver and increases the number of hepatic LDL receptors on the cell surface for enhanced uptake and catabolism of LDL. Atorvastatin reduces LDL production and the number of LDL particles. Atorvastatin produces a profound and sustained increase in LDL receptor activity coupled with a beneficial change in the quality of circulating LDL particles. Atorvastatin is effective in reducing LDL-C in patients with homozygous familial hypercholesterolaemia, a population that has not usually responded to<br />lipid-lowering medicinal products.<br />Atorvastatin has been shown to reduce concentrations of total-C (30% - 46%), LDL-C (41% - 61%), apolipoprotein B (34% - 50%), and triglycerides (14% - 33%) while producing variable increases in HDL-C and apolipoprotein A1 in a dose response study. These results are consistent in patients with heterozygous familial hypercholesterolaemia, nonfamilial forms of hypercholesterolaemia, and mixed hyperlipidaemia, including patients with noninsulin- dependent diabetes mellitus.<br />Clinical efficacy and safety<br />In controlled clinical studies, Ezetimibe/Atorvastatin significantly reduced total-C, LDL-C, Apo<br />19<br />B, and TG, and increased HDL-C in patients with hypercholesterolaemia.<br />Primary Hypercholesterolaemia<br />In a placebo-controlled study, 628 patients with hyperlipidaemia were randomised to receive placebo, ezetimibe (10 mg), atorvastatin (10 mg, 20 mg, 40 mg, or 80 mg), or co-administered Ezetimibe/Atorvastatin (10/10, 10/20, 10/40, and 10/80 mg) for up to 12-weeks.<br />Patients receiving all doses of Ezetimibe/Atorvastatin were compared to those receiving all doses of atorvastatin. Ezetimibe/Atorvastatin lowered total-C, LDL-C, Apo B, TG, and non-HDL-C, and increased HDL-C significantly more than atorvastatin alone. (See Table 4.)<br />20<br />Table 4<br />Response to Ezetimibe/Atorvastatin in Patients Hyperlipidaemia (Meana % Change from Untreated Baselineb at 12 weeks)<br />Treatment (Daily Dose)<br />N<br />Total-C<br />LDL-C<br />Apo B<br />TGa<br />HDL-C<br />Non-HDL-C<br />Pooled data (All Atorvastatin<br />/Ezetimibe doses)c<br />255<br />-41<br />-56<br />-45<br />-33<br />+7<br />-52<br />Pooled data (All atorvastatin doses)c<br />248<br />-32<br />-44<br />-36<br />-24<br />+4<br />-41<br />Ezetimibe 10 mg<br />65<br />-14<br />-20<br />-15<br />-5<br />+4<br />-18<br />Placebo<br />60<br />+4<br />+4<br />+3<br />-6<br />+4<br />+4<br />Ezetimibe/Atorvastatin dose<br />10/10<br />65<br />-38<br />-53<br />-43<br />-31<br />+9<br />-49<br />10/20<br />62<br />-39<br />-54<br />-44<br />-30<br />+9<br />-50<br />10/40<br />65<br />-42<br />-56<br />-45<br />-34<br />+5<br />-52<br />10/80<br />63<br />-46<br />-61<br />-50<br />-40<br />+7<br />-58<br />Atorvastatin by dose<br />10 mg<br />60<br />-26<br />-37<br />-28<br />-21<br />+6<br />-34<br />20 mg<br />60<br />-30<br />-42<br />-34<br />-23<br />+4<br />-39<br />40 mg<br />66<br />-32<br />-45<br />-37<br />-24<br />+4<br />-41<br />80 mg<br />62<br />-40<br />-54<br />-46<br />-31<br />+3<br />-51<br />a For triglycerides, median % change frombaseline<br />b Baseline - on no lipid-lowering medicinal product<br />c Ezetimibe/Atorvastatin pooled (10/10-10/80 mg) significantly reduced total-C, LDL-C, Apo B, TG, non- HDL-C, and significantly increased HDL-C compared to all doses of atorvastatin pooled (10-80 mg).<br />In a controlled study, the Titration of Atorvastatin vs Ezetimibe Add-On to Atorvastatin in Patients with Hypercholesterolaemia (TEMPO) study, 184 patients, with an LDL-C level &ge; 2.6 mmol/L and &le; 4.1 mmol/L and at moderate high risk for CHD, received atorvastatin 20 mg for a minimum of 4 weeks prior to randomisation. Patients not at an LDL-C level &lt; 2.6 mmol/L were randomised to receive either co-administered Ezetimibe/Atorvastatin 20/10 mg or atorvastatin 40 mg for 6 weeks.<br />Ezetimibe/Atorvastatin 10/20 mg was significantly more effective than doubling the dose of atorvastatin to 40 mg in further reducing total-C (-20% vs. -7%), LDL-C (-31% vs. -11%), Apo B (-21% vs. -8%), and non-HDL-C (-27% vs. -10%). Results for HDL-C and TG between the two treatment groups were not significantly different. Also, significantly more patients receiving Ezetimibe/Atorvastatin 10/20 mg attained LDL-C &lt; 2.6 mmol/L compared to those receiving atorvastatin 40 mg, 84% vs. 49%.<br />In a controlled study, The Ezetimibe Plus Atorvastatin vs Atorvastatin Titration in Achieving Lower LDL-C Targets in Hypercholesterolaemic Patients (EZ-PATH) study, 556 high- cardiovascular-risk patients with a LDL-C level &ge; 1.8 mmol/L and &le; 4.1 mmol/L received atorvastatin 40 mg for a minimum of 4 weeks prior to randomisation. Patients not at a LDL-C level &lt; 1.8 mmol/L were randomised to receive either co-administered Ezetimibe/Atorvastatin (10/40 mg) or atorvastatin 80 mg for 6 weeks.<br />21<br />Ezetimibe/Atorvastatin 10/40 mg was significantly more effective than doubling the dose of atorvastatin to 80 mg in further reducing total-C (-17% vs. -7%), LDL-C (-27% vs. -11%), Apo<br />B (-18% vs. -8%), TG (-12% vs. -6%), and non-HDL-C (-23% vs. -9%). Results for HDL-C between the two treatment groups were not significantly different. Also, significantly more patients receiving Ezetimibe/Atorvastatin 10/40 mg attained LDL-C &lt; 1.8 mmol/L compared to those receiving atorvastatin 80 mg, 74% vs. 32%.<br />In a placebo-controlled, 8-week study, 308 hypercholesterolaemic patients receiving atorvastatin and not at National Cholesterol Education Program (NCEP) LDL-C goal (LDL-C goal based upon baseline LDL-C and CHD risk status) were randomised to receive either ezetimibe 10 mg or placebo in addition to their on-going atorvastatin therapy.<br />Among patients not at LDL-C goal at baseline (~83%), significantly more patients receiving ezetimibe co-administered with atorvastatin achieved their LDL-C goal compared to patients receiving placebo co-administered with atorvastatin, 67% vs. 19%. Ezetimibe added to atorvastatin therapy lowered LDL-C significantly more than placebo added to atorvastatin therapy, 25% vs. 4%. Ezetimibe added to atorvastatin therapy also significantly decreased total- C, Apo B, and TG compared with placebo added to atorvastatin therapy.<br />In a controlled, 12-week, 2-phase study, 1,539 high-cardiovascular-risk patients, with a LDL-C level between 2.6 and 4.1 mmol/L, on atorvastatin 10 mg daily were randomised to receive: atorvastatin 20 mg, rosuvastatin 10 mg, or Ezetimibe/Atorvastatin 10/10 mg. After 6 weeks of treatment (Phase I), patients taking atorvastatin 20 mg who failed to achieve a LDL-C level &lt; 2.6 mmol/L were switched to either atorvastatin 40 mg or Ezetimibe/Atorvastatin 10/20 mg for 6 weeks (Phase II), and similar patients taking rosuvastatin 10 mg during Phase I were switched to either rosuvastatin 20 mg or Ezetimibe/Atorvastatin 10/20 mg. Reductions in LDL-C and comparisons between the Ezetimibe/Atorvastatin group and other treatment groups studied are shown in Table 5.<br />Table 5<br />Response to Ezetimibe/Atorvastatin* in High Risk Patients with a LDL-C Level Between 2.6 and 4.1 mmol/L on Atorvastatin 10 mg Daily at Baseline<br />Treatment<br />N<br />Percent Change from Baseline&dagger;<br />Total-C<br />LDL-C<br />Apo B<br />TG&Dagger;<br />HDL-C<br />Non-HDL-C<br />Phase I: Switched from atorvastatin 10 mg<br />Ezetimibe/Atorvastatin 10/10 mg<br />120<br />-13.5<br />-22.2<br />-11.3<br />-6.0<br />+0.6<br />-18.3<br />Atorvastatin 20 mg<br />480<br />-6.4&sect;<br />-9.5&sect;<br />-6.0&para;<br />-3.9<br />-1.1<br />-8.1&sect;<br />Rosuvastatin 10 mg<br />939<br />-7.7&sect;<br />-13.0&sect;<br />-6.9#<br />-1.1<br />+1.1<br />-10.6&sect;<br />Phase II: Switched from atorvastatin 20 mg<br />Ezetimibe/Atorvastatin 10/20 mg<br />124<br />-10.7<br />-17.4<br />-9.8<br />-5.9<br />+0.7<br />-15.1<br />Atorvastatin 40 mg<br />124<br />-3.8&THORN;<br />-6.9&THORN;<br />-5.4<br />-3.1<br />+1.7<br />-5.8&THORN;<br />Switched from rosuvastatin 10 mg<br />Ezetimibe/Atorvastatin 10/20 mg<br />231<br />-11.8<br />-17.1<br />-11.9<br />-0.2<br />+0.1<br />-16.2<br />Rosuvastatin 20 mg<br />205<br />-4.5&THORN;<br />-7.5&THORN;<br />-4.1&THORN;<br />-.2&szlig;<br />+0.8<br />-6.4&THORN;<br />* Co-administered of Ezetimibe/Atorvastatin 10/10 mg or Ezetimibe/Atorvastatin 10/20 mg<br />22<br />&dagger; M-Estimates (based on the method of Huber; 95% CI and p-value were obtained from fitting a robust Regression model with terms for treatment and baseline)<br />&Dagger; Geometric mean percent changes from baseline in TG were calculated based on back-transformation via exponentiation of the model-based least square (LS) means and expressed as (geometric mean &ndash; 1) multiplied by 100<br />&sect; p&lt;0.001 vs Ezetimibe/Atorvastatin 10/10 mg<br />&para; p&lt;0.01 vs Ezetimibe/Atorvastatin 10/10 mg # p&lt;0.05 vs Ezetimibe/Atorvastatin 10/10 mg &THORN; p&lt;0.001 vs Ezetimibe/Atorvastatin 10/20 mg &szlig; p&lt;0.05 vs Ezetimibe/Atorvastatin 10/20 mg<br />Table 5 does not contain data comparing the effects of Ezetimibe/Atorvastatin 10/10 mg or 10/20 mg to doses higher than atorvastatin 40 mg or rosuvastatin 20 mg.<br />In a placebo-controlled study, the Myocardial Ischaemia Reduction with Aggressive Cholesterol- Lowering (MIRACL) study, patients with an acute coronary syndrome (non Q-wave MI or unstable angina) were randomised to receive atorvastatin 80 mg/day (n = 1,538) or placebo (n = 1,548). Treatment was initiated during the acute phase after hospital admission and lasted for 16 weeks. Atorvastatin 80 mg/day provided a 16% (p = 0.048) reduction in risk of the combined primary endpoint: death from any cause, nonfatal MI, resuscitated cardiac arrest, or angina pectoris with evidence of myocardial ischaemia requiring hospitalisation. This was mainly due to a 26% reduction in re-hospitalisation for angina pectoris with evidence of myocardial ischaemia (p = 0.018).<br />Ezetimibe/Atorvastatin contains atorvastatin. In a placebo-controlled study, the Anglo- Scandinavian Cardiac Outcomes Trial Lipid-Lowering Arm (ASCOT-LLA), the effect of atorvastatin 10 mg on fatal and non-fatal CHD was assessed in 10,305 hypertensive patients, 40- 80 years old, with TC levels &le; 6.5 mmol/L and at least three cardiovascular risk factors. Patients were followed for a median duration of 3.3 years. Atorvastatin 10 mg significantly (p &lt; 0.001) reduced the relative risk for: fatal CHD plus nonfatal MI by 36% (absolute risk reduction = 1.1%); total cardiovascular events and revascularisation procedures by 20% (absolute risk reduction = 1.9%); and total coronary events by 29% (absolute risk reduction = 1.4%).<br />In a placebo-controlled study, the Collaborative Atorvastatin Diabetes Study (CARDS), the effect of atorvastatin 10 mg on cardiovascular disease (CVD) endpoints was assessed in 2838 patients, 40-75 years old, with type 2 diabetes, one or more cardiovascular risk factors, LDL &le;4.1 mmol/L, and TG &le; 6.8 mmol/L. Patients were followed for a median duration of 3.9 years. Atorvastatin 10 mg significantly (p &lt; 0.05) reduced: the rate of major cardiovascular events by 37% (absolute risk reduction = 3.2%); the risk of stroke by 48% (absolute risk reduction = 1.3%); and the risk of MI by 42% (absolute risk reduction = 1.9%).<br />Prevention of Cardiovascular Events<br />In an ezetimibe/simvastatin, multicentre, randomised, double-blind, active-control study, 18,144 patients enrolled within 10 days of hospitalisation for acute coronary syndrome (ACS; either acute myocardial infarction [MI] or unstable angina [UA]). All patients were randomised in a 1:1 ratio to receive either ezetimibe/simvastatin 10/40 mg (n = 9,067) or simvastatin 40 mg (n = 9,077) and followed for a median of 6.0 years.<br />23<br />Patients had a mean age of 63.6 years; 76% were male, 84% were Caucasian, and 27% were diabetic. The average LDL-C value at the time of study qualifying event was 80 mg/dL (2.1 mmol/L) for those on lipid-lowering therapy (n = 6,390) and 101 mg/dL (2.6 mmol/L) for those not on previous lipid-lowering therapy (n = 11,594). Prior to the hospitalisation for the qualifying ACS event, 34% of the patients were on statin therapy. At one-year, the average LDL- C for patients continuing on therapy was 53.2 mg/dL (1.4 mmol/L) for the ezetimibe/simvastatin group and 69.9 mg/dL (1.8 mmol/L) for the simvastatin monotherapy group.<br />The primary endpoint was a composite consisting of cardiovascular death, major coronary events (MCE; defined as non-fatal myocardial infarction, documented unstable angina that required hospitalisation, or any coronary revascularisation procedure occurring at least 30 days after randomised treatment assignment) and non-fatal stroke. The study demonstrated that treatment with ezetimibe/simvastatin provided incremental benefit in reducing the primary composite endpoint of cardiovascular death, MCE, and non-fatal stroke compared with simvastatin alone (relative risk reduction of 6.4%, p = 0.016). The primary endpoint occurred in 2,572 of 9,067 patients (7-year Kaplan-Meier [KM] rate 32.72%) in the ezetimibe/simvastatin group and 2,742 of 9,077 patients (7-year KM rate 34.67%) in the simvastatin alone group. (See Figure 1 and Table 6.) This incremental benefit is expected to be similar with co-administration of and Ezetimibe/Atorvastatin. Total mortality was unchanged in this high risk group.<br />There was an overall benefit for all strokes; however there was a small non-significant increase in haemorrhagic stroke in the ezetimibe-simvastatin group compared with simvastatin alone. The risk of haemorrhagic stroke for ezetimibe co-administered with higher potency statins in long- term outcome studies has not been evaluated.<br />The treatment effect of ezetimibe/simvastatin was generally consistent with the overall results across many subgroups, including sex, age, race, medical history of diabetes mellitus, baseline lipid levels, prior statin therapy, prior stroke, and hypertension.<br />Figure 1: Effect of ezetimibe/simvastatin on the Primary Composite Endpoint of Cardiovascular Death, Major Coronary Event, or Non-fatal Stroke<br />24<br />Table 6<br />Major Cardiovascular Events by Treatment Group in All Randomised Patients in IMPROVE-IT<br />Outcome<br />Ezetimibe/Simvastatin<br />10/40 mg* (N=9,067)<br />Simvastatin<br />40 mg&dagger; (N=9,077)<br />Hazard Ratio (95% CI)<br />p- value<br />n<br />K-M %&Dagger;<br />n<br />K-M %&Dagger;<br />Primary Composite Efficacy Endpoint<br />(CV death, Major Coronary Events and non-fatal stroke)<br />2,572<br />32.72%<br />2,742<br />34.67%<br />0.936 (0.887,<br />0.988)<br />0.016<br />Components of Primary Composite Endpoint and Select Efficacy Endpoints (first occurrences of specified event at any time)<br />Cardiovascular death<br />537<br />6.89%<br />538<br />6.84%<br />1.000 (0.887, 1.127)<br />0.997<br />Major Coronary Event:<br />Non-fatal MI<br />945<br />12.77%<br />1,083<br />14.41%<br />0.871 (0.798, 0.950)<br />0.002<br />Unstable angina requiring hospitalisation<br />156<br />2.06%<br />148<br />1.92%<br />1.059 (0.846, 1.326)<br />0.618<br />Coronary revascularisation after 30 days<br />1,690<br />21.84%<br />1,793<br />23.36%<br />0.947 (0.886, 1.012)<br />0.107<br />Non-fatal stroke<br />245<br />3.49%<br />305<br />4.24%<br />0.802 (0.678, 0.949)<br />0.010<br />* 6% were uptitrated to ezetimibe/simvastatin 10/80 mg<br />&dagger; 27% were uptitrated to simvastatin 80 mg<br />&Dagger; Kaplan-Meier estimate at 7 years<br />Homozygous Familial Hypercholesterolaemia (HoFH)<br />A double-blind, randomised, 12-week study was performed in patients with a clinical and/or genotypic diagnosis of HoFH. Data were analysed from a subgroup of patients (n = 36) receiving atorvastatin 40 mg at baseline. Increasing the dose of atorvastatin from 40 to 80 mg (n = 12) produced a reduction of LDL-C of 2% from baseline on atorvastatin 40 mg. Ezetimibe/Atorvastatin (40/10 and 80/10 pooled, n = 24), produced a reduction of LDL-C of 19% from baseline on atorvastatin 40 mg. In those patients co-administered Ezetimibe/Atorvastatin (80/10, n = 12), a reduction of LDL-C of 25% from baseline on atorvastatin 40 mg was produced.<br />After completing the 12-week study, eligible patients (n = 35), who were receiving atorvastatin 40 mg at baseline, were assigned to co-administered Ezetimibe/Atorvastatin 40/10 for up to an additional 24 months. Following at least 4 weeks of treatment, the atorvastatin dose could be doubled to a maximum dose of 80 mg. At the end of the 24 months, Ezetimibe/Atorvastatin (40/10 and 80/10 pooled) produced a reduction of LDL-C that was consistent with that seen in the 12-week study.<br />The European Medicines Agency has waived the obligation to submit the results of studies with Ezetimibe/Atorvastatin in all subsets of the paediatric population in the treatments of hypercholesterolaemia and mixed hyperlipidaemia (see section 4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption<br />Ezetimibe/Atorvastatin<br />The effects of a high-fat meal on the pharmacokinetics of Ezetimibe/Atorvastatin tablets are comparable to those reported for the individual tablets.<br />Ezetimibe<br />After oral administration, ezetimibe is rapidly absorbed and extensively conjugated to a pharmacologically active phenolic glucuronide (ezetimibe-glucuronide). Mean maximum plasma concentrations (Cmax) occur within 1 to 2 hours for ezetimibe-glucuronide and 4 to 12 hours for ezetimibe. The absolute bioavailability of ezetimibe cannot be determined as the compound is virtually insoluble in aqueous media suitable for injection.<br />Concomitant food administration (high-fat or non-fat meals) had no effect on the oral bioavailability of ezetimibe when administered as 10-mg tablets.<br />Atorvastatin<br />Atorvastatin is rapidly absorbed after oral administration; maximum plasma concentrations (Cmax) occur within 1 to 2 hours. Extent of absorption increases in proportion to atorvastatin dose. After oral administration, atorvastatin film-coated tablets are 95% to 99% bioavailable compared to the oral solution. The absolute bioavailability of atorvastatin is approximately 12% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%. The low systemic availability is attributed to presystemic clearance in gastrointestinal mucosa and/or hepatic first-pass metabolism.<br />Distribution<br />Ezetimibe<br />Ezetimibe and ezetimibe-glucuronide are bound 99.7% and 88 to 92% to human plasma proteins, respectively.<br />Atorvastatin<br />Mean volume of distribution of atorvastatin is approximately 381 l. Atorvastatin is &ge; 98% bound<br />to plasma proteins.<br />Biotransformation<br />Ezetimibe<br />Ezetimibe is metabolised primarily in the small intestine and liver via glucuronide conjugation (a phase II reaction) with subsequent biliary excretion. Minimal oxidative metabolism (a phase I reaction) has been observed in all species evaluated. Ezetimibe and ezetimibe-glucuronide are the major drug-derived compounds detected in plasma, constituting approximately 10 to 20% and 80 to 90% of the total drug in plasma, respectively. Both ezetimibe and ezetimibe-glucuronide are slowly eliminated from plasma with evidence of significant enterohepatic recycling. The half-life for ezetimibe and ezetimibe-glucuronide is approximately 22 hours.<br />26<br />Atorvastatin<br />Atorvastatin is metabolised by cytochrome P450 3A4 to ortho- and parahydroxylated derivatives and various beta-oxidation products. Apart from other pathways these products are further metabolised via glucuronidation. In vitro, inhibition of HMG-CoA reductase by ortho- and parahydroxylated metabolites is equivalent to that of atorvastatin. Approximately 70% of circulating inhibitory activity for HMG-CoA reductase is attributed to active metabolites.<br />Elimination<br />Ezetimibe<br />Following oral administration of 14C-ezetimibe (20 mg) to human subjects, total ezetimibe accounted for approximately 93% of the total radioactivity in plasma. Approximately 78% and 11% of the administered radioactivity were recovered in the faeces and urine, respectively, over a 10-day collection period. After 48 hours, there were no detectable levels of radioactivity in the plasma.<br />Atorvastatin<br />Atorvastatin is eliminated primarily in bile following hepatic and/or extrahepatic metabolism. However, the medicinal product does not appear to undergo significant enterohepatic recirculation. Mean plasma elimination half-life of atorvastatin in humans is approximately 14 hours. The half-life of inhibitory activity for HMG-CoA reductase is approximately 20 to 30 hours due to the contribution of active metabolites.<br />Atorvastatin is a substrate of the hepatic transporters, organic anion-transporting polypeptide 1B1 (OATP1B1) and 1B3 (OATP1B3) transporter. Metabolites of atorvastatin are substrates of OATP1B1. Atorvastatin is also identified as a substrate of the efflux transporters multi-drug resistance protein 1 (MDR1) and breast cancer resistance protein (BCRP), which may limit the intestinal absorption and biliary clearance of atorvastatin.<br />Paediatric population<br />Ezetimibe<br />The pharmacokinetics of ezetimibe are similar between children &ge; 6 years and adults. Pharmacokinetic data in the paediatric population &lt; 6 years of age are not available. Clinical experience in paediatric and adolescent patients includes patients with HoFH, HeFH, or sitosterolaemia.<br />Atorvastatin<br />In an open-label, 8-week study, Tanner Stage 1 (n = 15) and Tanner Stage 2 (n = 24) paediatric patients (ages 6-17 years) with heterozygous familial hypercholesterolaemia and baseline LDL-C<br />&ge; 4 mmol/L were treated with 5 or 10 mg of chewable or 10 or 20 mg of film-coated atorvastatin tablets once daily, respectively. Body weight was the only significant covariate in atorvastatin population PK model. Apparent oral clearance of atorvastatin in paediatric subjects appeared similar to adults when scaled allometrically by body weight. Consistent decreases in LDL-C and TC were observed over the range of atorvastatin and o-hydroxyatorvastatin exposures.<br />27<br />Elderly<br />Ezetimibe<br />Plasma concentrations for total ezetimibe are about 2-fold higher in the elderly (&ge; 65 years) than in the young (18 to 45 years). LDL-C reduction and safety profile are comparable between elderly and younger subjects treated with ezetimibe.<br />Atorvastatin<br />Plasma concentrations of atorvastatin and its active metabolites are higher in healthy elderly subjects than in young adults while the lipid effects were comparable to those seen in younger patient populations.<br />Hepatic impairment<br />Ezetimibe<br />After a single 10-mg dose of ezetimibe, the mean AUC for total ezetimibe was increased approximately 1.7-fold in patients with mild hepatic insufficiency (Child-Pugh score 5 or 6), compared to healthy subjects. In a 14-day, multiple-dose study (10 mg daily) in patients with moderate hepatic insufficiency (Child-Pugh score 7 to 9), the mean AUC for total ezetimibe was increased approximately 4-fold on Day 1 and Day 14 compared to healthy subjects. No dose adjustment is necessary for patients with mild hepatic insufficiency. Due to the unknown effects of the increased exposure to ezetimibe in patients with moderate or severe (Child-Pugh score &gt;<br />9) hepatic insufficiency, ezetimibe is not recommended in these patients (see sections 4.2 and 4.4).<br />Atorvastatin<br />Plasma concentrations of atorvastatin and its active metabolites are markedly increased (approx. 16-fold in Cmax and approx. 11-fold in AUC) in patients with chronic alcoholic liver disease (Child-Pugh B).<br />Renal impairment<br />Ezetimibe<br />After a single 10-mg dose of ezetimibe in patients with severe renal disease (n = 8; mean CrCl &le; 30 mL/min/1.73 m2), the mean AUC for total ezetimibe was increased approximately 1.5-fold, compared to healthy subjects (n = 9). An additional patient in this study (post-renal transplant and receiving multiple medicinal products, including ciclosporin) had a 12-fold greater exposure to total ezetimibe.<br />Atorvastatin<br />Renal disease has no influence on the plasma concentrations or lipid effects of atorvastatin and its active metabolites.<br />Gender<br />Ezetimibe<br />Plasma concentrations for total ezetimibe are slightly higher (approximately 20%) in women than in men. LDL-C reduction and safety profile are comparable between men and women treated with ezetimibe.<br />28<br />Atorvastatin<br />Concentrations of atorvastatin and its active metabolites in women differ from those in men (women: approx. 20% higher for Cmax and approx. 10% lower for AUC). These differences were of no clinical significance, resulting in no clinically significant differences in lipid effects among men and women.<br />SLCO1B1 polymorphism<br />Atorvastatin<br />Hepatic uptake of all HMG-CoA reductase inhibitors, including atorvastatin, involves the OATP1B1 transporter. In patients with SLCO1B1 polymorphism there is a risk of increased exposure of atorvastatin, which may lead to an increased risk of rhabdomyolysis (see section 4.4). Polymorphism in the gene encoding OATP1B1 (SLCO1B1 c.521CC) is associated with a 2.4-fold higher atorvastatin exposure (AUC) than in individuals without this genotype variant (c.521TT). A genetically impaired hepatic uptake of atorvastatin is also possible in these patients. Possible consequences for the efficacy are unknown.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ezetimibe/Atorvastatin<br />In three-month co-administration studies in rats and dogs with Ezetimibe/Atorvastatin the toxic effects observed were essentially those typically associated with statins. The statin-like histopathologic findings were limited to the liver. Some of the toxic effects were more pronounced than those observed during treatment with statins alone. This is attributed to pharmacokinetic and/or pharmacodynamic interactions following co-administration.<br />The co-administration of Ezetimibe/Atorvastatin in pregnant rats indicated that there was a test article-related increase in the skeletal variation &ldquo;reduced ossification of the sternebrae&rdquo; in the high dose (1,000/108.6 mg/kg) Ezetimibe/Atorvastatin group. This may be related to the observed decrease in foetal body weights. In pregnant rabbits a low incidence of skeletal deformities (fused sternebrae, fused caudal vertebrae and asymmetrical sternebrae variation) were observed.<br />In a series of in vivo and in vitro assays, ezetimibe, given alone or co-administered with atorvastatin, exhibited no genotoxic potential.<br />Ezetimibe<br />Animal studies on the chronic toxicity of ezetimibe identified no target organs for toxic effects. In dogs treated for four weeks with ezetimibe (&ge; 0.03 mg/kg/day) the cholesterol concentration in the cystic bile was increased by a factor of 2.5 to 3.5. However, in a one-year study on dogs given doses of up to 300 mg/kg/day no increased incidence of cholelithiasis or other hepatobiliary effects were observed. The significance of these data for humans is not known. A lithogenic risk associated with the therapeutic use of ezetimibe cannot be ruled out.<br />Long-term carcinogenicity tests on ezetimibe were negative.<br />Ezetimibe had no effect on the fertility of male or female rats, nor was it found to be teratogenic in rats or rabbits, nor did it affect prenatal or postnatal development. Ezetimibe crossed the placental barrier in pregnant rats and rabbits given multiple doses of 1,000 mg/kg/day.<br />29<br />Atorvastatin<br />Atorvastatin was negative for mutagenic and clastogenic potential in a battery of 4 in vitro tests and 1 in vivo assay. Atorvastatin was not found to be carcinogenic in rats, but high doses in mice (resulting in 6-11-fold the AUC0-24h reached in humans at the highest recommended dose) showed hepatocellular adenomas in males and hepatocellular carcinomas in females. There is evidence from animal experimental studies that HMG-CoA reductase inhibitors may affect the development of embryos or foetuses. In rats, rabbits, and dogs atorvastatin had no effect on fertility and was not teratogenic, however, at maternally toxic doses foetal toxicity was observed in rats and rabbits. The development of the rat offspring was delayed and post-natal survival reduced during exposure of the dams to high doses of atorvastatin. In rats, there is evidence of placental transfer. In rats, plasma concentrations of atorvastatin are similar to those in milk. It is not known whether atorvastatin or its metabolites are excreted in human milk.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tablet Core: Lactose Monohydrate, Croscarmellose Sodium, Polyvinyl Pyrrolidone, Sodium Lauryl Sulfate, Microcrystalline Cellulose, Magnesium Stearate, Calcium Carbonate, Hydroxy Propyl Cellulose, Polysorbate 80, Colloidal Anhydrous Silica.<br />Film Coat: Opadry-II White 31G58920 (consist of Hypromellose, Lactose Monohydrate, Titanium Dioxide, Macrogol/PEG MW 4000, Talc, Macrogol/PEG MW 400).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                18 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C in the original package in order to protect from moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Available in Alu-Alu Blister pack<br />Alu Alu blister of 10 tablets composed of Alu Alu cold form laminate foil and Aluminium Foil. Three such Alu-Alu blisters are packed in a carton along with insert.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Saudi Amarox Industrial Company
Al Jamiah Street, Al Malaz District
Riyadh 12629, Saudi Arabia
Tel & Fax: +966 11 226 8850
Manufacturer
IND-SWIFT LIMITED , India.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                November 2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>